Replacement mitral valves

Information

  • Patent Grant
  • 11026790
  • Patent Number
    11,026,790
  • Date Filed
    Tuesday, July 9, 2019
    5 years ago
  • Date Issued
    Tuesday, June 8, 2021
    3 years ago
Abstract
A prosthetic mitral valve includes an anchor assembly, a strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The ventricular anchor and the atrial anchor are configured to flare radially outwards relative to the central portion. The annular strut frame is disposed radially within the anchor assembly and is attached to the anchor assembly. The central portion is configured to align with a native valve orifice and the ventricular anchor and the atrial anchor are configured to compress native cardiac tissue therebetween.
Description
INCORPORATION BY REFERENCE

All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.


BACKGROUND

The mitral valve lies between the left atrium and the left ventricle of the heart. Various diseases can affect the function of the mitral valve, including degenerative mitral valve disease and mitral valve prolapse. These diseases can cause mitral stenosis, in which the valve fails to open fully and thereby obstructs blood flow, and/or mitral insufficiency, in which the mitral valve is incompetent and blood flows passively in the wrong direction.


Many patients with heart disease, including those with mitral valve problems, are intolerant of the trauma associated with open-heart surgery. Age or advanced illness may have impaired the patient's ability to recover from the injury of an open-heart procedure. Additionally, the high costs associated with open-heart surgery and extra-corporeal perfusion can make such procedures prohibitive.


Patients in need of cardiac valve repair or cardiac valve replacement can be served by minimally invasive surgical techniques. In many minimally invasive procedures, small devices are manipulated within the patient's body under visualization from a live imaging source like ultrasound, fluoroscopy, or endoscopy. Minimally invasive cardiac procedures are inherently less traumatic than open procedures and may be performed without extra-corporeal perfusion, which carries a significant risk of procedural complications.


Minimally invasive aortic valve replacement devices, such as the Medtronic Corevalve or the Edwards Sapien, deliver aortic valve prostheses through small tubes which may be positioned within the heart through the aorta via the femoral artery or through the apex of the heart. However, the mitral valve differs from the aortic valve in that the shape and anatomy immediately surrounding the valve varies greatly from one side of the valve to the other. Moreover, current cardiac valve prostheses are not designed to function effectively within the mitral valve. Further, current cardiac valve prostheses delivered via a minimally invasive device are often difficult to place correctly within the native valve, difficult to match in size to the native valve, and difficult to retrieve and replace if initially placed incorrectly.


These and other deficiencies in existing approaches are described herein.


SUMMARY OF THE DISCLOSURE

In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly, a strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The ventricular anchor and the atrial anchor are configured to flare radially outwards relative to the central portion. The annular strut frame is disposed radially within the anchor assembly and is attached to the anchor assembly at a plurality of attachment locations that are positioned between the central portion and an atrial-most edge of the anchor assembly. The central portion is configured to align with a native valve orifice and the ventricular anchor and the atrial anchor are configured to compress native cardiac tissue therebetween.


This and other embodiments can include one or more of the following features. An atrial end of the strut frame can be attached to the anchor assembly. Atrial tips of the strut frame can be attached to the anchor assembly. An atrial end of the strut frame can be flared radially outwards. A flare of the strut frame can be configured to substantially conform to a flare of the atrial anchor. A ventricular end of the strut frame can be spaced away from the anchor assembly. The ventricular end of the strut frame can be spaced away from the anchor assembly by a radial distance of 1-15 mm. The anchor assembly and the strut frame can be configured to self-expand from a constrained configuration to an expanded configuration. The strut frame can be attached to the anchor assembly with a plurality of rivets. Each of the plurality of attachment locations can be radially aligned with tips of the atrial anchor. The plurality of attachment locations can each be part of the anchor assembly that extends further radially inwards than a remaining portion of the anchor assembly. The anchor assembly can comprise a plurality of diamond-shaped cells. The plurality of attachment locations can be positioned at a mid-point of the outermost atrial diamond-shaped cells. The strut frame can include a plurality of linear struts and v-shaped connectors therebetween. The anchor assembly can form a substantially hour-glass shape.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly, an annular strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The ventricular anchor and the atrial anchor are configured to flare radially outwards relative to the central portion. Further, the anchor assembly comprises a plurality of diamond-shaped cells. The annular strut frame is disposed radially within the anchor assembly and is attached to the anchor assembly at a plurality of attachment locations that are positioned at a mid-point of the outermost atrial diamond-shaped cells between the central portion and an atrial-most edge of the anchor assembly.


This and other embodiments can include one or more of the following features. An atrial end of the strut frame can be attached to the anchor assembly. Atrial tips of the strut frame can be attached to the anchor assembly. An atrial end of the strut frame can be flared radially outwards. A flare of the strut frame can be configured to substantially conform to a flare of the atrial anchor. A ventricular end of the strut frame can be spaced away from the anchor assembly. The ventricular end of the strut frame can be spaced away from the anchor assembly by a radial distance of 1-15 mm. The anchor assembly and the strut frame can be configured to self-expand from a constrained configuration to an expanded configuration. The strut frame can be attached to the anchor assembly with a plurality of rivets. Each of the plurality of attachment locations can be radially aligned with tips of the atrial anchor. The plurality of attachment locations can each be part of the anchor assembly that extends further radially inwards than a remaining portion of the anchor assembly. The strut frame can include a plurality of linear struts and v-shaped connectors therebetween. The anchor assembly can form a substantially hour-glass shape.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly, an annular strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly further includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The ventricular anchor and the atrial anchor are configured to flare radially outwards relative to the central portion. Further, the atrial anchor includes a plurality of atrial cells and the ventricular anchor includes a plurality of ventricular cells. The annular strut frame is disposed radially within the anchor assembly. A first plurality of the atrial cells are positioned radially inwards relative to a second plurality of the atrial cells such that the first plurality of cells attach the strut frame to the anchor assembly.


This and other embodiments can include one or more of the following features. The central portion can be configured to align with a native valve orifice, and the ventricular anchor and the atrial anchor can be configured to compress native cardiac tissue therebetween. An atrial end of the strut frame can be attached to the anchor assembly. Atrial tips of the strut frame can be attached to the anchor assembly. An atrial end of the strut frame can be flared radially outwards. A flare of the strut frame can be configured to substantially conform to a flare of the atrial anchor. A ventricular end of the strut frame can be spaced away from the anchor assembly. The ventricular end of the strut frame can be spaced away from the anchor assembly by a radial distance of 1-15 mm. The anchor assembly and the strut frame can be configured to self-expand from a constrained configuration to an expanded configuration. The strut frame can be attached to the anchor assembly with a plurality of rivets. The first plurality of atrial cells can end in disconnected apexes. The disconnected apexes can be radially aligned with outer-most tips of the second plurality of atrial cells. The first plurality of atrial cells can be angled at approximately 70-80 degrees relative to the axis that extends through the central portion. The second plurality of atrial cells can be angled at approximately 20-30 degrees relative to the axis that extends through the central portion. The annular strut frame can flare radially outwards at 70-80 degrees relative to the axis that extends through the central portion.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly, an annular strut frame, and a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The ventricular anchor and the atrial anchor are configured to flare radially outwards relative to the central portion. Further, the atrial anchor includes a plurality of atrial cells. The annular strut frame is disposed radially within the anchor assembly. A first plurality of the atrial cells are interior disconnected apexes and the second plurality of atrial cells are outermost atrial cells. The first plurality positioned radially inwards relative to a second plurality of the atrial cells such that the first plurality of cells attach the strut frame to the anchor assembly.


This and other embodiments can include one or more of the following features. The central portion can be configured to align with a native valve orifice. The ventricular anchor and the atrial anchor can be configured to compress native cardiac tissue therebetween. An atrial end of the strut frame can be attached to the anchor assembly. Atrial tips of the strut frame can be attached to the anchor assembly. An atrial end of the strut frame can be flared radially outwards. A flare of the strut frame can be configured to substantially conform to a flare of the atrial anchor. A ventricular end of the strut frame can be spaced away from the anchor assembly. The ventricular end of the strut frame can be spaced away from the anchor assembly by a radial distance of 1-15 mm. The anchor assembly and the strut frame can be configured to self-expand from a constrained configuration to an expanded configuration. The strut frame can be attached to the anchor assembly with a plurality of rivets. The disconnected apexes can be radially aligned with outer-most tips of the second plurality of atrial cells. The first plurality of atrial cells can be angled at approximately 70-80 degrees relative to an axis that extends through the central portion. The second plurality of atrial cells can be angled at approximately 20-30 degrees relative to the axis that extends through the central portion. The annular strut frame can flare radially outwards at 70-80 degrees relative to the axis that extends through the central portion.


In general, in one embodiment, a prosthetic mitral valve includes a valve support assembly that includes a ventricular anchor and an atrial anchor. The valve support assembly has a plurality of slots therethrough. The prosthetic mitral valve further includes a plurality of replacement leaflets. Each leaflet has a leaflet arm extending through one of the plurality of slots. The prosthetic mitral valve further includes a plurality of commissure plates. Each commissure plate is circumferentially and axially aligned with one of the plurality of slots to form a commissure attachment mechanism. Each commissure plate further includes a plurality of channels in the sides thereof. The at least one suture is positioned at each commissure attachment mechanism and is wrapped around a portion of the valve support assembly, through the plurality of indents, and around the commis sure plate.


This and other embodiments can include one or more of the following features. The valve support assembly can include an anchor assembly that includes the ventricular and atrial anchors and an annular strut frame that includes the plurality of slots. The annular strut frame can be positioned radially within the anchor assembly. The plurality of slots can be in a portion of the strut frame that extends past the anchor assembly in the ventricular direction. The anchor assembly can further include a central portion, and the ventricular and atrial anchors can flare radially outwards relative to the central portion. The plurality of channels can extend from the sides of each commissure plate towards a center of the plate. The plurality of channels can be substantially straight. There can be between 6 and 12 channels in each commissure plate. Each of the slots can be in an axially extending strut. Arms of the leaflets can extend through the plurality of slots. The arms can be further be wound around an outer perimeter of an inner strut frame of the valve support assembly. The plurality of slots can be positioned equidistance around a circumference of the valve support assembly. Each of the plurality of slots can be positioned towards a ventricular end of the valve support assembly. The valve support assembly can be configured to self-expand from a constrained configuration to an expanded configuration. Atrial edges of the leaflets can be sewn around an inner circumference of the valve support assembly. Each of the leaflets further includes a leaflet protector thereon. The leaflet protector can be made of a lubricious fabric and can be configured to protect the respective leaflet from an inner circumference of the valve support assembly.


In general, in one embodiment, a prosthetic mitral valve includes a valve support assembly. The valve support assembly includes an anchor assembly having a ventricular anchor and an atrial anchor and an annular strut frame positioned radially within the anchor assembly. The annular strut frame includes a plurality of slots therethrough. The prosthetic mitral valve further includes a plurality of replacement leaflets. Each leaflet has a leaflet arm extending through one of the plurality of slots. The prosthetic mitral valve further includes a plurality of commissure plates. Each commissure plate is circumferentially and axially aligned with one of the plurality of slots to form a commissure attachment mechanism. Each commissure plate further includes a plurality of channels in the sides thereof.


This and other embodiments can include one or more of the following features. The prosthetic mitral valve can include at least one suture at each commissure attachment mechanism. The at least one suture can be positioned around the strut frame, through the plurality of indents, and around the commissure plate. The plurality of slots can be in a portion of the strut frame that extends past the anchor assembly in the ventricular direction. The anchor assembly can further include a central portion, and the ventricular and atrial anchors can be flared radially outwards relative to the central portion. The plurality of channels can extend from the sides of each commis sure plate towards a center of the plate. The plurality of channels can be substantially straight. There can be between 6 and 12 channels in each commissure plate. Each of the slots can be in an axially extending strut. The arms of the leaflets can extend through the plurality of slots. The arms can be further be wound around an outer perimeter of the strut frame. The plurality of slots can be positioned equidistance around a circumference of the strut frame. Each of the plurality of slots can be positioned towards a ventricular end of the strut frame. The valve support assembly can be configured to self-expand from a constrained configuration to an expanded configuration. Atrial edges of the leaflets can be sewn around an inner circumference of the strut frame. Each of the leaflets can further include a leaflet protector thereon. The leaflet protector can be made of a lubricious fabric and can be configured to protect the leaflet from an inner circumference of the valve support assembly.


In general, in one embodiment, a prosthetic mitral valve includes a valve support assembly, a plurality of leaflets secured to the valve support assembly, and a plurality of retention hooks. The valve support assembly includes a ventricular anchor, a central portion, and an atrial anchor. The valve support assembly is configured to self-expand from a collapsed configuration to an expanded configuration. The plurality of retention hooks are attached to the ventricular anchor. Each of the retention hooks curves radially outwards to point in an atrial direction when the valve support assembly is in the expanded configuration. Each retention hook has a ratio of radius of curvature to thickness of greater than 4:1.


This and other embodiments can include one or more of the following features. Each of the plurality of retention hooks can be configured to point at an angle of 50°-80° relative to a central longitudinal axis of the prosthetic mitral valve. The angle can be approximately 65°. A radius of curvature of each of the plurality of retention hooks can be between 3-5 mm. A thickness of each retention hooks can be between 0.8 mm and 1.6 mm. The plurality of retention hooks can be integral with the valve support assembly. The valve support assembly can include an anchor assembly that further includes the ventricular and atrial anchors and the central portion and an annular strut frame positioned radially within the anchor assembly. The plurality of retention hooks can be attached to the anchor assembly. The central portion can be configured to align with a native valve orifice, and the ventricular anchor and the atrial anchors can be configured to compress native cardiac tissue therebetween. The valve support assembly can include a plurality of diamond-shaped cells. Each of the retention hooks can extend from an apex of an interior diamond-shaped cell. A retention hook can extend from each apex in a circumferential line around the prosthetic mitral valve except at positions closest to leaflet attachment points.


In general, in one embodiment, a prosthetic mitral valve includes a valve support assembly, a plurality of leaflets secured to the valve support assembly, and a plurality of retention hooks. The valve support assembly includes a ventricular anchor, a central portion, and an atrial anchor. Each of the retention hooks is attached to the ventricular anchor and curves radially outwards to point in an atrial direction. Each retention hook has a ratio of radius of curvature to thickness of greater than 4:1 and points at an angle of 10°-40° relative to a central longitudinal axis of the prosthetic mitral valve.


This and other embodiments can include one or more of the following features. The angle can be approximately 65°. A radius of curvature of each of the plurality of retention hooks can be between 3-5 mm. A thickness of each retention hooks can be between 0.8 mm and 1.6 mm.


The plurality of retention hooks can be integral with the valve support assembly. The valve support assembly can include an anchor assembly that further includes the ventricular and atrial anchors and the central portion and an annular strut frame positioned radially within the anchor assembly. The plurality of retention hooks can be attached to the anchor assembly. The central portion can be configured to align with a native valve orifice, and the ventricular anchor and the atrial anchors can be configured to compress native cardiac tissue therebetween. The valve support assembly can include a plurality of diamond-shaped cells. Each of the retention hooks can extend from an apex of an interior diamond-shaped cell. A retention hook can extend from each apex in a circumferential line around the prosthetic mitral valve except at positions closest to leaflet attachment points.


In general, in one embodiment, a replacement mitral valve includes a self-expandable valve support assembly that includes a ventricular anchor, a central portion, and an atrial anchor. The valve support assembly has a self-expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The atrial anchor has a larger diameter than the ventricular anchor when the valve assembly is in the self-expanded configuration. The replacement mitral valve further includes a plurality of replacement leaflets secured to the valve assembly.


This and other embodiments can include one or more of the following features. The ventricular anchor can have outer diameter of less than 55 mm. The atrial anchor can have diameter that is 3-10% larger than diameter of ventricular anchor. The valve support assembly can include an anchor assembly that includes the central portion and ventricular and atrial anchors. The valve support assembly can further include an annular strut frame positioned radially within the anchor assembly. The anchor assembly can be made of a plurality of diamond-shaped cells joined together. The valve support assembly can be configured to self-expand from a constrained configuration to an expanded configuration. The anchor assembly can be configured to foreshorten when transitioning from the constrained configuration to the expanded configuration. The anchor assembly can be configured to take on an hour-glass shape. Tips of the atrial anchor can point in a ventricular direction. The atrial and ventricular anchors can be configured to compress native cardiac tissue therebetween. The atrial anchor can include a plurality of atrial tips and the ventricular anchor can include a plurality of ventricular tips. There can be more ventricular tips than atrial tips.


In general, in one embodiment, a replacement mitral valve includes a valve support assembly that includes a ventricular anchor, a central portion, and an atrial anchor. The valve support assembly has a self-expanded configuration in which the ventricular anchor and the atrial anchor are flared radially outward relative to the central portion. The atrial anchor has a diameter that is 3-10% larger than a diameter of the ventricular anchor. The replacement mitral valve further includes a plurality of replacement leaflets secured to the valve assembly.


This and other embodiments can include one or more of the following features. The ventricular anchor can have outer diameter of less than 55 mm. The valve support assembly can include an anchor assembly including the central portion and ventricular and atrial anchors. The valve support assembly can further include an annular strut frame positioned radially within the anchor assembly. The anchor assembly can be made of a plurality of diamond-shaped cells joined together. The valve support assembly can be configured to self-expand from a constrained configuration to an expanded configuration. The anchor assembly can be configured to foreshorten when transitioning from the constrained configuration to the expanded configuration. The anchor assembly can be configured to take on an hour-glass shape. Tips of the atrial anchor can point in a ventricular direction. The atrial and ventricular anchors can be configured to compress native cardiac tissue therebetween. The atrial anchor can include a plurality of atrial tips and the ventricular anchor can include a plurality of ventricular tips. There can be more ventricular tips than atrial tips.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly that includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The anchor assembly is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor. An annular strut frame is disposed radially within the anchor assembly and attached thereto. The prosthetic mitral valve further includes a plurality of replacement leaflets secured to the annular strut frame. The anchor assembly and annular strut frame are configured to self expand from a collapsed configuration to an expanded configuration. The anchor assembly is configured to foreshorten along a central axis of the prosthetic mitral valve when expanding from the collapsed configuration to the expanded configuration. The annular strut frame is configured to be substantially nonforeshortening along the central axis when expanding from the collapsed configuration to the expanded configuration.


This and other embodiments can include one or more of the following features. The anchor assembly can include a plurality of diamond-shaped cells. The ventricular anchor can include a plurality of struts and v-shaped connecting members. The ventricular anchor and atrial anchors can flare radially outwards relative to the central portion when in the expanded configuration. The anchor assembly can be configured to foreshorten by 20-30% when self-expanding from the collapsed configuration to the expanded configuration.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly that includes a ventricular anchor, an atrial anchor, and a central portion therebetween. The anchor assembly is configured to compress native cardiac tissue between the ventricular anchor and the atrial anchor. An annular strut frame is disposed radially within the anchor assembly such that the annular strut frame is spaced radially away from the central portion of the anchor assembly. The prosthetic mitral valve further includes a plurality of replacement leaflets secured to the annular strut frame.


This and other embodiments can include one or more of the following features. The annular strut frame can be spaced radially away from the central portion by 2-3 mm. The annular strut frame can be flared at an atrial end. Atrial tips of the annular strut frame can be attached to the anchor assembly. A portion of the anchor assembly can be pulled radially inwards relative to a remainder of the anchor assembly so as to attach to the annular strut frame.


In general, in one embodiment, a prosthetic mitral valve includes a valve assembly that includes a ventricular anchor, a central portion, and an atrial anchor. The anchor assembly is configured to expand from a collapsed configuration to an expanded configuration. The atrial anchor includes a plurality of atrial cells forming peaks and valleys around a circumference thereof, and the ventricular anchor includes a plurality of ventricular cells forming peaks and valleys around a circumference thereof. A plurality of replacement leaflets are secured to the valve assembly. A plurality of retention hooks are attached only to the ventricular anchor. Each of the plurality of retention hooks is positioned in a valley between the ventricular cells when the valve assembly is in the expanded configuration.


This and other embodiments can include one or more of the following features. The plurality of retention hooks can curve to point in the atrial direction when the anchor assembly is in the expanded configuration. The valve assembly can be configured to self-expand. The plurality of retention hooks can point at an angle of 50°-80° relative to a horizontal axis of the prosthetic mitral valve. The plurality of retention hooks can be positioned in every valley except valleys closest to leaflet attachment points.


In general, in one embodiment, a prosthetic mitral valve includes an anchor assembly that includes a ventricular anchor, a central portion, and an atrial anchor. The anchor assembly configured to expand from a collapsed configuration to an expanded configuration. The atrial anchor includes a plurality of atrial cells at an atrial edge of the atrial anchor, and the ventricular anchor includes a plurality of ventricular cells at a ventricular edge of the ventricular anchor. The number of ventricular cells is divisible by 2, and the number of atrial cells is divisible by 3. An annular strut frame is positioned within the anchor assembly and includes a plurality of struts connected by connection members. Three of the struts include commissure attachment points. The three commis sure attachment points are spaced equally around a circumference of the annular strut frame. Three replacement leaflets are secured to the annular strut frame at the commissure attachment points.


This and other embodiments can include one or more of the following features. There can be 30 ventricular cells, 15 atrial cells, and 15 struts. There can be 24 ventricular cells, 12 atrial cells, and 12 struts. There can be more ventricular cells than atrial cells. The number of ventricular cells can also be divisible by 3.


In general, in one embodiment, a prosthetic mitral valve includes a valve support assembly, a plurality of leaflets, and a plurality of retention hooks. The valve support assembly includes a ventricular anchor, a central portion, and an atrial anchor. The valve support assembly is configured to self-expand from a collapsed configuration to an expanded configuration. The plurality of leaflets are secured to the valve support assembly, and the plurality of retention hooks are attached to the ventricular anchor. Each of the retention hooks curves radially outwards to point in an atrial direction when the valve support assembly is in the expanded configuration, and each retention hook has a ratio of radius of curvature to thickness of 4:1 or greater.


This and other embodiments can include one or more of the following features. The ratio can be between 4:1 and 8:1. Each of the plurality of retention hooks can be configured to point at an angle of 10-40 degrees relative to a central longitudinal axis of the prosthetic mitral valve. The angle can be approximately 28°. A radius of curvature of each of the plurality of retention hooks can be less than 4 mm. A radius of curvature of each of the plurality of retention hooks can be between 2 mm-4 mm. A thickness of each of the plurality of retention hooks can be less than 1.6 mm. A thickness of each retention hooks can be between 0.25 mm and 1 mm. A ratio of width to thickness of each retention hook can be between 0.3:1 and 1:1. Each hook can be configured to engage approximately 3-10 mm of mitral valve tissue when the valve support assembly is in the expanded configuration. The plurality of retention hooks can be integral with the valve support assembly. The valve support assembly can include an anchor assembly including the ventricular and atrial anchors and the central portion and an annular strut frame positioned radially within the anchor assembly. The plurality of retention hooks can be attached to the anchor assembly. The central portion can be configured to align with a native valve orifice, and the ventricular anchor and the atrial anchors can be configured to compress native cardiac tissue therebetween. The valve support assembly can include a plurality of diamond-shaped cells, and each of the retention hooks can extend from an apex of an interior diamond-shaped cell. A retention hook can extend from each apex in a circumferential line around the prosthetic mitral valve except a position closest to a leaflet attachment point.


In general, in one embodiment, a prosthetic mitral valve includes a valve support assembly, a plurality of leaflets, and a plurality of retention hooks. The valve support includes a ventricular anchor, a central portion, and an atrial anchor. The plurality of leaflets are secured to the valve support assembly, and the plurality of retention hooks are attached to the ventricular anchor. Each of the retention hooks curves radially outwards to point in an atrial direction, and each retention hook has a ratio of radius of curvature to thickness of greater than 4:1 and points at an angle of 10°-40° relative to a central longitudinal axis of the prosthetic mitral valve.


This and other embodiments can include one or more of the following features. A ratio of width to thickness of each retention hook can be between 0.3:1 and 1:1. Each hook can be configured to engage approximately 3-10 mm of mitral valve tissue when the valve support assembly is in the expanded configuration. A radius of curvature of each of the plurality of retention hooks can be less than 4 mm.





BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIGS. 1A-1C show an exemplary mitral valve prosthesis. FIGS. 1A-1B show the mitral valve prosthesis in an expanded configuration. FIG. 1C shows a portion of the expanded anchor assembly in 2D.



FIGS. 2A-2E show another exemplary mitral valve prosthesis. FIGS. 2A-2B show the mitral valve prosthesis in an expanded configuration. FIG. 2C shows a portion of the expanded anchor assembly in 2D. FIG. 2D shows the expanded annular strut frame. FIG. 2E shows a 2D pattern (pre-expanded) for the strut frame.



FIG. 3A-3C show another exemplary mitral valve prosthesis. FIGS. 3A-3B show the mitral valve prosthesis in an expanded configuration. FIG. 3C shows the expanded annular strut frame.



FIGS. 4A-4C show another exemplary mitral valve prosthesis in an expanded configuration.



FIGS. 5A-5C show an exemplary nonforeshortening anchor assembly in the expanded configuration.



FIGS. 6A-6C show another exemplary nonforeshortening anchor assembly in the expanded configuration.



FIGS. 7A-7B show an exemplary anchor assembly before it is heat-set into an hour-glass shape.



FIGS. 8A-8G show another exemplary mitral valve prosthesis. FIGS. 8A-8C show the mitral valve prosthesis in the expanded configuration. FIGS. 8D-8E show the expanded anchor assembly. FIG. 8F shows a portion of the expanded anchor assembly in 2D. FIG. 8G shows a 2D pattern (pre-expanded) for the anchor assembly.



FIGS. 9A-9D show another exemplary nonforeshortening anchor assembly. FIGS. 9A-9C show the anchor assembly in the expanded configuration. FIG. 9D shows a 2D pattern (pre-expanded) for the anchor assembly.



FIG. 10 shows an exemplary valve assembly including the anchor assembly, strut frame, skirt, and leaflets.



FIGS. 11A-11E show one exemplary mechanism of attaching leaflets to the strut frame. FIG. 11A shows an exemplary commissure plate. FIG. 11B shows a cross-sectional view of leaflets extending between the two commissure plates. FIG. 11C shows a valve assembly having a strut with a series of holes therein for attachment of leaflets to the valve assembly. FIG. 11D shows a cross-sectional view of the leaflets and commissure plates attached to the strut. FIG. 11E shows a close-up of a portion of the strut with holes therein.



FIG. 12 shows another exemplary mechanism of attaching leaflets to the strut frame.



FIGS. 13A-13B show deployment of a ventricular anchor of an exemplary mitral valve prosthesis out of a sheath.



FIG. 14 is a cross-section showing another exemplary mechanism of attaching leaflets.



FIG. 15A-15C show another exemplary mechanism of attaching leaflets. FIG. 15A shows a secondary member including a slot. FIG. 15B is a cross-sectional view showing the leaflets passed through the slot of the secondary member and around a strut of the strut frame. FIG. 15C shows alignment of the secondary member and the strut.



FIGS. 16A-16D show a holder including an exemplary mitral valve prosthesis with a skirt or covering.



FIGS. 17A-17J show an exemplary method of deploying a valve prostheses.



FIGS. 18A-18E show another exemplary mechanism of attaching leaflets to the strut frame. FIG. 18A shows a plate attached to a valve assembly to attach the leaflets thereto. FIGS. 18B is a cross-sectional view showing the leaflets attached between the plate and a strut. FIG. 18C is a top view of the exemplary mechanism. FIG. 18D shows the plate positioned over two leaflets and a strut of the valve assembly. FIG. 18E shows the plate attached to the strut frame.



FIG. 19 shows a method of sewing leaflets around the circumference of the strut frame.



FIGS. 20A-20Q show another exemplary mitral valve prosthesis. FIG. 20A shows the exemplary mitral valve prosthesis in the expanded configuration. FIGS. 20B-20C show the expanded prosthesis without the leaflets or skirt for clarity. FIGS. 20D-20G show the expanded anchor assembly. FIG. 20H shows the atrial end of the expanded valve prosthesis. FIG. 20I shows the ventricular end of the expanded valve prosthesis. FIG. 20J is a 2D view of the (unexpanded) anchor assembly. FIG. 20K shows the expanded strut frame. FIG. 20L is a 2D view of the (unexpanded) strut frame. FIG. 20M is a side view of the strut frame. FIG. 20N is a top (atrial) view of the strut frame. FIG. 20O is another view of the expanded anchor assembly. FIGS. 20P-20Q are additional view of the expanded prosthesis without the leaflets or skirt for clarity.



FIG. 21 shows an exemplary leaflet for use with the mitral valve prostheses described herein.



FIG. 22 shows the inflow edges of the leaflets sewn to the strut frame



FIGS. 23A-23C show an exemplary mitral valve prosthesis with a skirt covering thereon.



FIGS. 24A-24C show an exemplary mitral valve prosthesis with a first set of dimensions.



FIGS. 25A-25C show an exemplary mitral valve prosthesis with a second set of dimensions.



FIG. 26 shows an exemplary mandrel for shaping a skirt.



FIGS. 27A-27Q show another exemplary method of attaching leaflets to a mitral valve prosthesis. FIG. 27A shows a strut frame with a slot in the strut and a first suture positioned therearound. FIG. 27B shows a second suture positioned therearound. FIG. 27C shows a third suture positioned therearound. FIG. 27D shows the alignment of leaflet protectors. FIG. 27E shows the positioning of the leaflets such that they are flush with one another. FIGS. 27F-27H show placement of the leaflet arms through the slot in the strut frame. FIG. 27I shows separation of the two leaflets to attach at additional commissure points. FIG. 27J shows an inflow view of the leaflets after they have been attached at the commissure attachment points. FIG. 27K shows an outflow view of the leaflets after they have been attached at the commissure attachment points. FIG. 27L shows the arms of the leaflets wrapped around the strut frame. FIG. 27M shows the leaflet protectors wrapped inside of the strut frame. FIG. 27N shows alignment of the leaflet arms with the strut frame. FIG. 27O shows placement of the plate over the strut frame. FIG. 27P shows wrapping of two sutures around the plate. FIG. 27Q shows wrapping of the final suture around the plate to attach the leaflets to the strut frame.



FIG. 28 shows placement of an exemplary valve prosthesis in the native mitral valve orifice.



FIGS. 29A-29E show a mitral valve prosthesis with a delivery system attachment mechanism. FIG. 29A shows the expanded valve assembly with pins therein. FIG. 29B shows a close-up of a pin. FIG. 29C shows slots in the skirt to allow for access to the pins. FIG. 29D shows a 2D (unexpanded) view of the anchor assembly with pins. FIG. 29E shows a close-up of a pin with dimensions.



FIG. 30 shows another exemplary mitral valve prosthesis with a skirt thereon.



FIGS. 31A-31C show exemplary hooks for a mitral valve prosthesis.



FIG. 32 shows an engagement radius R of hooks on a mitral valve prosthesis.



FIG. 33 shows an exemplary plate for leaflet attachment.



FIG. 34 shows another exemplary plate for leaflet attachment.



FIG. 35 shows an exemplary tubular pre-formed skirt.



FIGS. 36A-36B show an exemplary anchor assembly and strut frame with a skirt extending thereover.



FIGS. 37A-37B show additional exemplary mitral valve prostheses without the leaflets or skirt.





DETAILED DESCRIPTION

This disclosure includes replacement heart valves (also referred to herein as prosthetic heart valves), methods of manufacturing replacement heart valves, including subassemblies thereof, and methods of using replacement heart valves. This disclosure describes the prostheses in the context of replacement mitral valves, but it is conceivable that the prostheses herein can be used or modified to be used as other replacement heart valves. In some embodiments, the replacement heart valves are self-orienting replacement mitral valves configured to be delivered using minimally invasive techniques.


The replacement heart valves described herein include an anchor assembly that includes an atrial anchor (e.g., configured to be placed on an atrial side of a mitral valve annulus), a ventricular anchor (e.g., configured to be placed on a ventricular side of a mitral valve annulus), and a central portion positioned axially between the atrial and ventricular anchors. The anchor assembly is adapted to collapse to a delivery or collapsed configuration and expand to an expanded configuration. The replacement heart valves also include a strut frame secured to at least one of the central portion, the ventricular anchor, or the atrial anchor for attaching a plurality of replacement leaflets thereto. The strut frame can be configured to deform and collapse as the rest of the anchor assembly is collapsed. The struts of the strut frame extend towards and/or past the ventricular anchor.


The replacement heart valves described herein are configured to be secured in the native valve orifice by sandwiching the cardiac orifice between ventricular and atrial anchors, which are larger in diameter than the valve orifice, by applying an axial compressive force from the anchors, a radial force from the center portion outward against the cardiac orifice, and/or by using hooks or barbs that extend into the tissue of the orifice.


Further, the replacement heart valves described herein can be delivered to a cardiac valve orifice, such as the mitral valve, by using minimally invasive techniques to access the cardiac valve. In some embodiments, the mitral valve prostheses can be delivered through a transatrial route, i.e., by making a small incision in the patient's body and passing the prosthesis through the apex of the heart to, for example, the mitral valve. In other embodiments, the mitral valve prostheses can be delivered through the transseptal route, i.e., through the venous system and into the left atrium via a transseptal puncture. In both the transatrial and transseptal delivery methods, the distal-most anchor can be delivered to the ventricle while the proximal-most anchor can be delivered to the atrium.



FIGS. 1A-1C show an exemplary mitral valve prosthesis 100 in an expanded configuration. The portion of the replacement valve prosthesis 100 in FIG. 1 may be referred to as a prosthesis subassembly, which includes an anchor assembly 101 and a strut frame 105, but excludes leaflets and any skirts that may be incorporated into the final replacement valve. Anchor assembly 101 includes an atrial anchor 102, a ventricular anchor 104, and a central portion 103 therebetween. In this embodiment, atrial anchor 102 is configured and adapted to be disposed on an atrial side of a mitral valve orifice, and ventricular anchor 104 is configured and adapted to be disposed on a ventricle side of the mitral valve orifice. Further, the central portion 103 can be configured to be situated in the mitral valve orifice. In some embodiments, the central portion 103 has a diameter that is substantially the same size as the native mitral valve annulus (i.e., it is not designed to be larger than the annulus).


In some embodiments, the anchor assembly 101 and/or strut frame 105 can be made of wire, such as a shape memory metal wire (e.g., a nitinol). In other embodiments, the anchor assembly and/or strut frame can be laser cut from one or more tubes, such as a shape memory metal tube (e.g., nitinol). For example, the anchor assembly 101 can be laser cut from a first hypotube while the strut frame 105 can be laser cut from a second hypotube of smaller diameter. The anchor assembly 101 can be cut, for example, from a 9-12 mm diameter tube, such as a 10 mm tube, while the strut frame 105 can be cut, for example, from a 7-9 mm diameter tube, such as an 8 mm tube.


The valve prosthesis 100 can be configured to expand (e.g., self-expand) from a collapsed or constrained (delivery) configuration to an expanded (treatment) configuration. In the expanded configuration shown in FIGS. 1A-1B, the atrial anchor 102 and ventricular anchor 104 extend radially outward from central portion 103, and are considered to flare outward relative to central portion 103. The atrial anchor 102 and ventricular anchor 104 can also be considered flanged relative to central portion 103. The flared configuration of atrial and ventricular anchors 102 and 104 relative to central portion 103 is described in the context of a side view of the anchor assembly, as can be best seen in FIG. 1B. In some embodiments, the flared configuration of the two anchors 102, 104 and the central portion 103 define a general hour-glass shape in a side view of the anchor assembly 101. That is, the anchors 102, 104 can be flared outwards relative to the central portion 103 and then curved or bent to point at least partially back in the axial direction. It should be understood, however, that an hour-glass configuration is not limited to symmetrical configuration.


The anchor assembly 101 can be configured to expand circumferentially and foreshorten axially as the valve prosthesis 100 expands from the collapsed delivery configuration to the expanded treatment configuration. For example, as shown in FIGS. 1A-1C, the anchor assembly 101 can be made of a plurality of cells 111 that are each configured to expand circumferentially and foreshorten axially upon expansion of the anchor assembly 101. As shown best in FIG. 1C, the cells 111 can each be diamond-shaped. Further, the cells 111 can be interconnected and configured such that every diamond apex 117 is connected to another diamond apex 117 except at the atrial or ventricular tips 112, 114 of the assembly 101. The anchor assembly 101 can include, for example, three circumferential rows of diamond cells 111. For example, the atrial anchor 102 can comprises one row of diamond-shaped cells 111 extending circumferentially, the central portion 103 can comprise one row of diamond-shaped cells 111 extending circumferentially, and the ventricular anchor 104 can comprise one row of diamond-shaped cells extending circumferentially 111.


The strut frame 105 can be configured to expand circumferentially, but maintain the same axial dimension (i.e., be non-foreshortening) as the valve prosthesis 100 expands from the collapsed delivery configuration to the expanded treatment configuration. By being non-foreshortening, the strut frame 105 can advantageously ensure that less strain is placed on the leaflets during delivery and/or packing. Thus, while the anchor assembly 101 is designed to be foreshortening, the strut frame 105 is designed so as to be substantially non-foreshortening. As can be best seen in FIG. 1B, the strut frame 105 can include a plurality of longitudinally extending struts 151 and interconnecting v-shaped members 153. Further, in some embodiments, and again as shown in FIGS. 1A-1B, the strut frame 105 can have fewer v-shaped members 151 extending circumferentially around the diameter thereof than the cells 111 of the anchor assembly 101, such as half the number. Further, the strut frame 105 can flare at radially outwards at the atrial end, e.g., to conform to the flare of the atrial anchor 102.


The strut frame 105 and the anchor assembly 101 can be coupled together with coupling members, such as rivets. In some embodiments, and as shown in FIGS. 1A-1B, the atrial tips 129 of the strut frame 105 can be coupled to the atrial tips 112 of the anchor assembly 101. Where there are fewer v-shaped members 151 in the strut frame 105 than cells 111 in the anchor assembly 101 (as shown in FIG. 1B), the strut frame 105 can attach to every other atrial tip 112 on the anchor assembly 101.


The radially inner surfaces of strut frame 105 can substantially define the perimeter of a central opening 106. Replacement leaflets, which are not shown in FIGS. 1A-1B for clarity, can be secured to the strut frame 105 and can be disposed at least partially in the central opening 106. The leaflets are configured to control blood flow therethrough.


In some embodiments, the valve 100 can include hooks 188 or barbs to help anchor the assembly in the mitral valve orifice. As shown in FIGS. 1A-1C, in one embodiment, the hooks 188 can be on the ventricular most tips 114 of the ventricular anchor 104.



FIGS. 2A-2E show another exemplary valve prosthesis 200. The valve prosthesis 200 is similar to valve prosthesis 100 and can include many of the same features as valve prosthesis 100, such as an anchor assembly 201 (having atrial anchor 202, a ventricular anchor 204, and a central portion 203) and a strut frame 205. In contrast to the prosthesis 100, the cells 211 of the anchor 201 are not connected together at every interior apex 217. Rather, the middle row of cells 211 can be disconnected at every other atrial apex 219 at the atrial side. As a result, there can be fewer atrial tips 212 than ventricular tips 214, and the atrial-most cells can be truncated or v-shaped (i.e., straddling each disconnected apex 219 and corresponding diamond-shaped cell). For example, there can be 15 atrial tips 212 (and 15 v-shaped cells 211 at the atrial end) and 30 ventricular tips 214 (and 30 diamond-shaped cells at the ventricular end). Advantageously, because the atrial tips 212 are larger/wider than the ventricular tips 214, the atrial tips 212 can be more flexible to allow the atrial anchor 202 to conform to the tissue. The atrial apexes 219 can be radially aligned with the atrial tips 212 and can be positioned approximately mid-way along the diamond-shaped cells at the atrial tips 212 along the central longitudinal axis (as noted above, the outermost cells can also be considered v-shaped, particularly in 2D, as the inner cell and apex 219 sit within the outer larger diamond, making it a v-shape).


In some embodiments, each of the atrial apexes 219 can have a rivet hole therein for connection to the atrial tips 229 of the strut frame 205. Further, in some embodiments (and as shown in FIGS. 2A and 2B), the atrial apexes 219 can all be bent slightly radially inwards towards the strut frame 205 (e.g., further radially inwards than the rest of the anchor assembly 201 so as to meet the strut frame 205). The atrial apexes 219 can be radially aligned with the atrial tips 212 of the atrial anchor 202. Further, the apexes 219, when bent radially inwards, can effectively act as an integrated suspension, holding the central portion 203 and ventricular anchor 204 radially outwards relative to, and spatially separated from, the strut frame 205. For example, the ventricular anchor 204 can be separated from the strut frame 205 by a radial distance of, for example, 1-15 mm, such as 2-11 mm, such as approximately 3 mm. Further, the central portion 203 can be separated from the strut frame 205 by a radial distance of, for example, 2-3 mm. This separation of the ventricular anchor 204 and/or the central portion 203 can advantageously isolate the leaflets from the anchor assembly 201 on the ventricular side where the greatest amount of distortion is placed on the anchor assembly 201.


Further, in this embodiment, the strut frame 205 and anchor assembly 201 can be attached at a central point of the atrial anchor 202 (i.e., at apexes 219) rather than at the outer-most or atrial-most tips 212 of the atrial anchor 202. By attaching the inner strut frame 205 to the anchor assembly 201 at a mid-point of the atrial anchor 202 rather than at the atrial tips 212, less torque or torsion is applied to the strut frame 205 as the atrial anchor 202 conforms to the tissue, thereby helping to ensure that the leaflets maintain their required position.


As shown best in FIGS. 2D and 2E, the strut frame 205 can include a plurality of struts 221 and v-shaped members 223 (so as to be substantially non-foreshortening as described with respect to strut frame 105). In this embodiment, there are four v-shaped members 223 extending axially between each pair of struts 221. The two ventricular-most v-shaped members 223 and the atrial-most v-shaped member 223 all point in the atrial direction. The last v-shaped member 223 points in the ventricular direction. Having a v-shaped member 223 that points in the ventricular direction can add to the stiffness of the strut frame 205. Additionally, having the last v-shaped member 223 point towards the atrium reduces the length of the struts and reduces the number of vertices that are pointed into the ventricle (to reduce trauma to the ventricle). The atrial tips 229 of the strut frame 205 can be formed by the vertex of the “V” shape. Each atrial tip 229 can include a rivet hole therein for connection to the anchor assembly 201. Further, the strut frame 205 can include a flare at the atrial end thereof to enable the strut frame to meet the apexes 219 and/or to conform to the flare of the atrial anchor 202. Further, in some embodiments (and as shown in FIG. 2D), the flare at the atrial end of the strut frame 205 can include relatively flexible members 209 or zig-zag features therein. The flexible members 209 can be configured to allow the atrial flare to easily fold up during packing/delivery.


In some embodiments, the number of ventricular cells or ventricular tips 214 in valve 200 (or any valve described herein) can be divisible by both 2 and 3. For example, there can be 18, 24, or 30 ventricular cells or tips 214. Because the number of ventricular tips 214 is divisible by 2, there can be half as many atrial tips 212. Further, by having the number of cells divisible by 3, the three attachment points for the three leaflets (e.g., struts 221a,b,c) of the strut frame 205 can be even spaced around the circumference of the central opening 206. Increasing the number of ventricular tips/cells (e.g., from 18 cells to 30 cells) in any given design means that the total amount of required circumferential expansion of each individual cell decreases, thereby allowing the longitudinal lengths of the cells to be shorter, decreasing the overall length of the packed assembly (i.e., during delivery). In some embodiments, the cells have a length of between 4 and 6 mm and a width of between 0.2 and 0.4 mm when collapsed, e.g., before expansion. With these dimensions, the packed assembly can be, for example, 30-40 mm, such as 32-35 mm. Further, in some embodiments, the cell dimensions are chosen such that the ratio of width to length yields no more than 8-10% sheathing strain when the anchor assembly is retracted into the catheter for delivery.



FIGS. 3A-3C show another exemplary valve prosthesis 300. Valve prosthesis 300 is similar to valve prosthesis 200 (with anchor assembly 301 similar to assembly 201). The strut frame 305, however, includes reduced thickness members 310 in the atrial flare rather than flexible members 209. The reduced thickness members 310 can have a smaller diameter than the rest of the strut frame 305. The reduced thickness members 310, similar to the flexible members 209, can allow for easier bending at the flare of the strut frame 305, thereby permitting easy packing.



FIGS. 4A-4C show another exemplary valve prosthesis 400. The valve 400 is similar to valves 100-300 except that the attachment point between the strut frame 405 and the anchor assembly 401 is at the ventricular end of the strut frame 405. To connect the anchor assembly 401 to the ventricular end of the strut frame 405, connecting members 494 extend from the anchor assembly 401 (e.g., from the central portion 403 or the ventricular anchor 404) to the ventricular tips of the strut frame 405. The connecting members 494 can be integral, for example, with the anchor assembly 401 and then riveted to the strut frame 405. In some embodiments, as shown in FIGS. 4A-4C, the connecting members 414 can be a single longitudinal member. In other embodiments, the connecting members 494 can be cells or tips 414 of the ventricular anchor 404 that are pulled radially inwards (e.g., every other tip 414 of the ventricular anchor 404 can be pulled inwards). Further, in some embodiments, an additional layer of cells can be coupled or riveted to the ventricular anchor 404 to tune the rigidity thereof. As shown in FIGS. 4A-4C, the atrial end of the strut frame 405 can still be flared at an angle, e.g., to substantially confirm to the flare of the atrial anchor 402 of the anchor assembly 401.



FIGS. 8A-8G show another exemplary valve prosthesis 800 including valve assembly 801 and strut frame 805. Valve prosthesis 800 is similar to valve prosthesis 200 except that valve prosthesis 800 has a greater curvature on the flare of the ventricular anchor 804, which can help improve retention force in some embodiments. For example, the ventricular anchor 804 can flare at an initial angle of 5°-15°, such as 10°, relative to a horizontal plane through the central portion 803 (and/or 75°-95°, such as 80°, relative to a central axis through the prosthesis 800). Additionally, the anchor assembly 801 includes a plurality of barbs or hooks 888 extending from the ventricular anchor 804. Positioning the hooks on the ventricular anchor 804 advantageously helps hold the prosthesis in place, as the ventricular side of the mitral valve undergoes the highest pressure. The hooks 888 are positioned in the valleys between the ventricular tips 814. Further, each hook 888, when the anchor assembly 801 is in the expanded configuration, is curved backwards to point at least partially in the atrial direction.



FIGS. 20A-20Q show another exemplary valve prosthesis 2000 including a valve assembly 2001 and a strut frame 2005. Prosthesis 2000 is similar to valve prosthesis 800 except that that the tips 2014 of the ventricular anchor 2004, after flaring radially outwards at the angle of 5-15° relative to the horizontal plane 2020, can curve away from the horizontal axis 2020 to point substantially in the axial (ventricular) direction, such as at an angle of 60-70°, such as 67° relative to the horizontal plane 2020. The curvatures of the two portions can be between 2 mm and 8 mm, respectively. Similarly, the atrial anchor 2002 can extend at an initial angle of 20°-30°, such as approximately 26°, relative to the horizontal plane 2020 through the central portion 2003. The tips 2012 of the atrial cells can then curve away from the axis 2020 to point more in the axial (atrial) direction, such as at an angle of 60-70°, such as 67° relative to the horizontal plane 2020. The curvatures of the two portions can be between 2 mm and 8 mm, respectively. Further, the atrial apexes 2019 with the rivet holes therein can extend at an angle of approximately 50-70°, such as 60° relative to the axis 2020, to meet and affix to the strut frame 2050. Similarly, the atrial tips 2029 of the strut frame 2005 can flare out at approximately 70°-80° relative to the horizontal axis 2020 so as to substantially conform to the flare of the atrial apexes 2019. There can be 30 atrial cells along a single circumference and only 15 ventricular cells.


Further, as is best shown in FIGS. 20K-20N, the strut frame 2005 is different from the strut frame 805 in that the strut frame 2205 does not include flexible members (e.g., zig-zag features) in the flare at the atrial end of the strut frame 2005. Rather, the connecting member on the anchoring structure can be made more compliant Like strut frame 205, the strut frame 2005 includes a plurality of struts 2021 and v-shaped member 2023 so as to be non-foreshortening. In strut frame 2005, however, there are five v-shaped members 2023 extending between each pair of struts 2021 rather than four. The extra v-shaped member 2023 is positioned proximate to the atrial-most v-shaped member 2023 and extends from the struts 2023 in the atrial direction. The extra v-shaped member can advantageously add circumferential strength to the strut frame 2005. The strut frame 2005 can further include one or more slots 2733 in the struts 2021 to allow for attachment of leaflets, as described below.


The anchor assembly 2001 also includes barbs or hooks 2088 that, similar to hooks 888, are positioned between the ventricular tips 2014 in the valleys and are curved backwards towards the atrial end. Further, in some embodiments, and as shown at FIGS. 20O-20Q, the hooks 2088 can be positioned between every ventricular cell 2011 (e.g., in the valleys) except those valleys closest to the commissure attachment points. At those points, one or more (such as one, two, or three) of the hooks 2088 can be removed so as to prevent interference with the commissures and/or leaflets when the prosthesis is in the collapsed configuration.


In some embodiments, such as for the anchor assembly 2000, the atrial anchor 2002 can have a larger diameter than the ventricular anchor 2004. Having a larger atrial anchor 2002 than a ventricular anchor 2004 allows the anchors 2002, 2004 to grip tissue while preventing the ventricular anchor 2004 from impeding flow to the aortic valve. That is, as shown in FIG. 28, if the ventricular anchor is too large, then the Left Ventricular Outflow Tract (LVOT) 2828 may be obstructed and restrict flow through the adjacent aortic valve 2829. In some embodiments, for example, the atrial anchor 2002 can have a diameter that is 3-10% larger than the diameter of the ventricular anchor 2004. The ventricular anchor 2004 can thus be less than 55 mm, such as less than or equal to 54 mm, such as less than or equal to 52 mm.


As described above, the number of ventricular cells or ventricular tips in any of the valves described herein can be divisible by both 2 and 3. For example, as shown in FIG. 37A, there can be 30 ventricular tips and 15 atrial tips. As another example, there can be 24 ventricular tips and 12 atrial tips, as shown in FIG. 37B.


In some embodiments, the prostheses described herein can be made in a plurality of different sizes so as to fit within a range of native valve orifice sizes. For example, referring to FIGS. 24A-24C, in some embodiments, a valve prosthesis 2400 can have an atrial anchor 2402 with an outer diameter of 54 mm, a ventricular anchor 2404 with an outer diameter of 52 mm, and a central portion 2403 with an outer diameter of 36 mm. Further, the strut frame 2405 can have an inner diameter of 27 mm-30 mm, such as approximately 29 mm. A total height of the prosthesis 2400 can be, for example, 22-28 mm, such as 26 mm. In contrast, the valve prosthesis 2500 of FIGS. 25A-25C can have a larger diameter to fit within a larger native valve orifice. For example, the atrial anchor 2502 can have an outer diameter of 59 mm, the ventricular anchor can have an outer diameter of 54 mm, and the central portion 2503 can have an outer diameter of 40 mm. The strut frame 2505, like the strut frame 2405, can have an inner diameter of 27 mm-30 mm, such as 29 mm. To compensate for the increased diameter of the valve assembly 2501 relative to the strut frame 2505, the disconnected atrial apexes 2519 can be pulled further radially inwards (for example, the disconnected atrial apexes 2519 can be pulled downwards in an s-shape to reach further inwards). A total length of the expanded valve 2500 can be 28-29 mm. Further, in order to maintain low packing strain, the sheathed or packed length of the valve 2500 can be longer than the packed length of the valve 2400. For example, the packed length of valve 2400 can be 32 mm-35 mm while the packed length of valve 2500 can be 34 mm-37 mm.


Anchor assemblies 101-401, 801, 2001, 2401, and 2501 all foreshorten upon expansion (due to their cellular design). For example, the anchor assemblies can foreshorten by 20%-30%. In contrast, the corresponding strut frames 105-405, 805, 2005, 2405, and 2505 maintain substantially the same axial length.


In some embodiments, the prosthesis can be designed such that the entire prosthesis does not foreshorten during expansion. Having the prosthesis not foreshorten advantageously allows the packed length to be much shorter, such as less than 35 mm, such than 30 mm, or less than 25 mm.


For example, FIGS. 5A-5C show an anchor assembly 501 that includes a plurality of struts 505 and circumferential v-shaped connectors 507 that do not substantially foreshorten upon expansion. The anchor assembly 501 forms a primarily hour-glass shape in the expanded configuration. Further, the atrial end includes flexible members 519 (e.g., zig-zag members) to aid in conforming to the native orifice.



FIGS. 6A-6C show another exemplary nonforeshortening anchor assembly 601 with a plurality of struts 605 and circumferential v-shaped connectors 607. In this embodiment, the ventricular anchor 604 is curled inwards at the tips to minimize interaction with the native ventricular anatomy.



FIGS. 9A-9D show another exemplary nonforeshortening anchor assembly 901 with a plurality of struts 905 and circumferential v-shaped connectors 907. In this embodiment, there are 5 v-shaped connectors 907 extending between each set of struts 905. The ventricular ends of the ventricular anchor 904, like ventricular anchor 604, curl in at the tips to minimize interaction with the native anatomy. Further, the struts 905 each include a flexible portion 929 (e.g., zig-zag or serpentine section) that extends from the atrial tips to the central portion 903. The flexible portions 929 aid in conforming the atrial anchor 902 to the native orifice. In this embodiment, the strut frame (which can be any strut frame described herein) can be configured to attached mid-way along the atrial anchor 902, such as rivet location 939. Advantageously, by attaching the strut frame at the atrial anchor (i.e., rather than the ventricular anchor), the strut frame can be less prone to distortion that can occur when the ventricular anchor is expanded during delivery.


Various hook or barb mechanisms can be used with any of the valves described herein. For example, the barb or hook can be riveted to the anchor assembly, can be laser cut from the assembly, and/ can be formed as part of a v-shaped feature of the anchor assembly. The hook or barb mechanisms can be designed such that they point radially outwards during deployment (i.e., not into the tissue) and do not engage with tissue until fully released, thereby preventing interference with the deployment. This can be achieved, for example, by using a hook having the proper radius of curvature to thickness ratio.


In some embodiments, the hooks can be on the ventricular most tips of the ventricular anchor, as shown in FIGS. 1A-1C. In other embodiments, the hooks can be in the valleys (i.e., between petals or tips, as shown in FIGS. 8A-8G and 20A-N). For example, the hooks can be placed in valleys on the ventricular anchor (e.g., from an apex of an interior diamond-shaped cell). When positioned between valleys on the ventricular anchor, the hooks can curve around and point in the atrial direction at an angle of 40°-90°, e.g., 50°-80°, e.g., 57-67°, such as about 62° relative to a horizontal axis of the device (or up to 50°, e.g., 10°-40°, such as 23°-33°, such as about 28° relative to a central longitudinal axis of the device). This angle can advantageously allow the hooks to point in the atrial direction to dig into tissue.


Referring to FIGS. 31A-31C, each hook 3188 on implant 3100 (which can be any implant described herein) can arc along an angle a of between 99°-119°, such as 104°-114°, such as approximately 109. Further, each hook 3188 can have a ratio of radius of curvature RC to thickness T of 4:1 or greater. Having a ratio of radius of curvature RC to thickness T of 4:1 or greater ensures that the hooks 3188 can bend from their curved configuration to lay flat during collapse (e.g., for delivery). In some embodiments, a radio of width W to thickness T of each hook 3188 can be between 0.3:1 and 1:1, such as between 0.4:1 and 0.6:1. Having a ratio within this range advantageously ensures that the hooks 3188 don't twist or bend sideways when collapsed or laid flat (e.g., for delivery of the implant).


In some embodiments, the ratio of radius of curvature RC to thickness T is between 4:1 and 10:1, such as between 5:1 and 9:1. The radius of curvature RC can, for example, be less than 4 mm, such as between 2 mm and 4 mm, such as between 2.5 mm and 3.5 mm, such as approximately 3 mm. The thickness T of the hook can be less than 1.6 mm, such as between 0.25 mm and 1 mm, such as between 0.3 mm and 0.5 mm, such as between 0.39 mm and 0.45 mm, such as approximately 0.42 mm. The width W of the hook can be between 0.1 mm and 0.4 mm, such as between 0.2 mm and 0.3 mm, such as approximately 0.22 mm.


In one exemplary embodiment, the radius of curvature of the hook is 3 mm, the thickness of the hook is 0.42 mm, and the width of the hook is 0.22 mm. The ratio of radius of curvature to thickness is therefore approximately 7.1:1, and the ratio of width to thickness is therefore 0.5:1.


Referring to FIG. 32, in some embodiments, the hooks 3288 on an implant 3200 (which can be any implant described herein) can be configured to engage tissue (e.g., extend within tissue of the native mitral valve annulus) at a radius R of between 2-20 mm, such as 3-10 mm, such as approximately 3.4 mm. Having a radius of engagement within this range advantageously ensures that the hooks 3288 can engage with tissue even when the native valve is not circular while ensuring that the hooks 3288 do not interfere with the adjacent aortic valve. For example, the diameter D1 of the implant 3200 at the connection of each hook 3288 (e.g., radially inner most point of the hooks) can be 30-50 mm, such as 40-48 mm, such as approximately 45 mm. The diameter D2 of the implant 3200 at the tip of each hook 3288 (e.g., the radially outer most point of the hook) can be 40-60 mm, such as 45-55 mm, such as 52 mm.


In some embodiments, the hooks can be riveted to the anchor assembly. In other embodiments (as shown in FIGS. 7A-7B), the hooks can be tabs that are flared out from the anchor assembly.


In some embodiments, as shown in FIGS. 9A-9D, a portion of the anchor assembly 901 can include a portion that is pointed radially outwards to act as a hook or barb in the tissue. For example, one set of the v-shaped circumferential members 907 can be bent to point outwards. The bent v-shaped members can be positioned, for example, on the inner diameter of the ventricular anchor 904 pointing towards the atrium.


Any of the valve prostheses described herein can include a fabric cover and/or skirt on one or more portions of the device. For example, referring to FIGS. 16A-16D (valve is shown in a holder for clarity), a covering or skirt 1616 can be sewn along the inner diameter of the atrial anchor 1616 and the flare of the strut frame 1605 and down the entire inner diameter of the strut frame 1605. This skirt 1616 can thus provide a smooth entrance for blood into the leaflets 1622. Further, the skirt 1616 can extend along the entire outer diameter of the anchoring assembly and then around the tips of the ventricular anchor 1604. In some embodiments, the skirt 1616 can be a single piece while in other embodiments, the skirt 1616 can be made of a plurality of pieces.


In some embodiments, as shown in FIG. 20A, the skirt 2016 can leave the ventricular tips of the ventricular anchor 2004 uncovered. In other embodiments, as shown in FIG. 30, the skirt 3006 can be wrapped fully around the ventricular tips of the ventricular anchor 3004.


In some embodiments, the skirt, or a portion of the skirt, can be knit in a three-dimensional shape, e.g., an hour glass shape, to help maintain a consistent seal of the skirt against the prosthesis and to help pack the skirt-covered prosthesis during delivery. For example, as shown in FIGS. 23A-23C, the skirt 2316 can be cut in an hour-glass shape and configured to cover all of the exposed sections of the valve on the atrial side (leaving only the ventricular side of the ventricular anchor and the outer diameter of the strut frame uncovered).


Further, in some embodiments, and as shown in FIGS. 23A-23C, the skirt 2316 can be cut in a saw-tooth pattern on the ventricular side to mimic the pattern of cells that extend to the outermost diameter of the ventricular anchor. Cutting the skirt in such a manner can help pack the ventricular anchor into the delivery device by reducing the packed diameter of the ventricular anchor.


Referring to FIG. 35, a skirt 3516 can be pre-formed as a tubular three-dimensional structure. The skirt 3516 can have a wide section 3535 configured to form around the outside or external surface of the anchor assembly and a narrow section 3553 configured to form against the inside or internal surface of the strut frame. The central section 3552 between the wide section 3535 and the narrow section 3552 can have a tapered diameter. The skirt 3515 can be wrapped around the anchor assembly and strut frame such that the first end 3554 is positioned at the tips of the ventricular anchor, the wide portion 3535 conforms to the outside of the anchor assembly, the tapered central section 3552 extends between the atrial anchor and the atrial end of the strut frame, and the narrow section 3553 is folded or everted into the strut frame so as to conform to the interior surface of the strut frame (with the second end 3555 positioned at the ventricular end of the strut frame). As shown, the first end 3554 can have a saw-tooth pattern so as to mimic the points of the cells forming the ventricular anchor and/or the second end 3555 can have a saw-tooth pattern so as to mimic the apexes at the ventricular end of the strut frame. In some embodiments, the skirt 3516 can have pre-formed cuts (e.g., laser cuts) to provide access to hooks, commissure attachment mechanisms, delivery system attachment mechanisms, or other elements of the underlying frame.



FIG. 36 shows a skirt 3616 that is formed and wrapped around the valve similar to as described with respect to skirt 3516. In this embodiment, however, the first and second ends 3654, 3655 are not in a saw-tooth configuration. Rather, the end 3654 is straight and ends at the tips of the ventricular anchor 3604 while the end 3655 is straight and is wrapped around the tips of the ventricular end of the strut frame 3605. It should be understood that one or both of the ends 3655, 3654 could be saw-tooth, one or both could be wrapped, and/or or one or both could end at the tips. Further, the skirt 3655 can be sewn to the frame (e.g., with polyethylene sutures) at the edges thereof.


Referring to FIG. 26, if a skirt is knit or otherwise formed in a three-dimensional shape, an inner mandrel 2626 can be used (i.e., the skirt can be knit or formed over the mandrel). After the skirt has been formed around the mandrel 2626, the mandrel 2626 can dissolve or otherwise break apart to leave the formed skirt. In some embodiments, a woven fabric, such as a polyester weave, can be used to form the skirt over the mandrel 2626. In other embodiments, a polyurethane layer can be painted or otherwise applied over the mandrel 2626. The polyurethane can advantageously create fewer wrinkles than a woven fabric. If a polyurethane layer is used, a flap of material may be added in order to create some give in the skirt as the valve is packed and/or unpacked. Further, in some embodiments, one or more polyurethane layers can be added after the skirt is sewn onto the frame (e.g., to fill in any holes caused by sewing the skirt to the frame the material).


The skirts described herein can be made of polyethylene terephalate (PET), polyester, or PET with a polyurethane dispersion.


The skirt can advantageously help block blood flow from one side of the valve over the other. The skirt can also help prevent the anatomy from having an adverse interaction with the frame itself.


In some embodiments, a coupler can be used to connect the strut frame to the anchor assembly. Rivets herein are an example of a coupler. The locations where components are secured to one another may be referred to as a coupling herein. Coupling also refers to the two components that are secured together. Riveting as used herein is an example of a method that plastically deforms a coupler to secure two or more components together at a coupling. Coupling and rivets are described further in U.S. patent application Ser. No. 14/677,334, filed Apr. 2, 2015, titled “REPLACEMENT CARDIAC VALVES AND METHODS OF USE AND MANUFACTURE,” the entire contents of which are incorporated by reference herein.


In some embodiments, the valve prostheses have been shown without leaflets for clarity. It is to be understood that each of the embodiments described herein can include replacement leaflets 1022a,b,c attached thereto, as shown in FIG. 10. An exemplary leaflet 2122 is shown in FIG. 21. The leaflet can include an outflow (or free) edge 2191 configured to float within the strut frame, an inflow edge 2193 configured to be sewn to the strut frame, and two arms 2195a,b. A plurality of sewing holes 2197 can provide for sewing of the leaflet 2122 to the strut frame. Thus, as shown in FIG. 19, the outer circumference of the leaflets at the inflow edges can be sewn to the strut frame and/or to the skirt covering the skirt frame. That is, while the commissures or edges of the leaflets can be attached as described above, the inflow edges of the leaflets can be sewn all around the circumference of the strut frame.


Further, the leaflets can be attached to any of the valve prosthesis designs in a variety of different ways.


For example, referring to FIGS. 11A-11F, two commissure plates 1010a,b can be used to sandwich the arms of the leaflets 1022a,b therebetween. The leaflets 1022a,b can then be sewn together (and to the plates 1010a,b) with one or more suture 1011 through holes 1013a,bc. After being sewn together, the joined leaflets and commissure plates can then be attached to the strut frame 1105 through, for example, a series of holes 1113a,b,c in one of the struts 1121 using a suture 1017 (which can be the same or different than suture 1011). The commissure plates 1010a,b can be made, for example, of stainless steel or plastic. Advantageously, the commissure plates 1010a,b can apply compression to the leaflets 1022a,b and distribute strains along the length of the commis sure plates, thereby reducing tearing or strain propagation through the tissue.


Another exemplary mechanism for leaflet attachment is shown in FIG. 12. Here, rather than using two commissure plates, a single u-shaped plate 1110 with a set of holes on either side can be used. In contrast to the commissure plates 1010a,b, the plate 1110 can place a fixed amount of compression on the leaflets that are sandwiched therebetween.


Additional exemplary mechanisms for leaflet attachment are shown in FIGS. 14 and 15A-15C. In the version of FIG. 14, the arms of two leaflets 1022a,b are pulled through a slot 1333 that is part of a strut 1321 of the strut frame. A secondary member 1313 having a width greater than the width of the slot 1313 is placed against both arms leaflets, and then the arms of the leaflets 1022a,b are wrapped around the secondary member 11313 and attached together with a suture 1311 or staple. The secondary member 1313 can be coupled to the strut frame, for example with a rivet. In a similar embodiment, shown in FIGS. 15A-15C, the leaflets 1022a,b can be passed through a slot in a secondary member 1515 and then wrapped around a strut 1521 of the strut frame. Advantageously, the mechanisms of FIGS. 14 and 15A-C evenly distribute high stress areas of leaflet along the length of strut 1312 or riveted slot 1321. The load distribution along the given length of these members decrease stresses in comparison to attachment methods where many stress concentrations are created i.e. sutures.


Another exemplary mechanism for leaflet attachment is shown in FIGS. 18A-18E. In this embodiment, a plate 1818 including a plurality of holes 1819 can be positioned on the outside of the strut frame 1805. Further, the strut frame 1805 can include a slot 1833 therethrough. The arms of the leaflets 1822a,b can then be extended through the slot 1833 and flattened against the outer surface of the strut frame 1805. The plate 1818 can be placed against the arms of the leaflets 1822a,b and then sutured to the arms of the leaflets, e.g., through the holes 1819. The arms of the leaflets 1822a,b can thus be sandwiched between the plate 1818 and the strut frame 1805. In some embodiments, the suture is attached to a skirt or fabric layer on the strut frame 1805 rather than directly to the strut frame.


Another exemplary mechanism for leaflet attachment is shown in FIGS. 27A-27R. In this embodiment, a plate 2727 with a plurality of channels 2773 (or open slots or indents) in the sides thereof can be positioned on the outside of the strut frame 2705. The channels 2773 can extend diagonally towards the center of the plate 2727. There can be two or more channels 2773, such as between 6 and 12 channels 2773, such as ten channels 2773. Further, the frame 2705 can include three slots 2733 therethrough (one for each attachment point) that are positioned equidistant from one another around the circumference of the strut frame 2705. The slots 2733 can be positioned within a strut 2721 at the ventricular end. To attach the leaflets 2722a,b to the frame 2705, a first suture 2772a can first be threaded between the frame 2705 and skirt 2716 fabric and around the slot 2733. The first suture 2772a can then be slid distally towards the ventricular tips 2777 of the strut frame 2705 (FIG. 27A). At FIG. 27B, a second suture 2772b is threaded similarly to the first suture 2772a. At FIG. 27C, a third suture 2772c is pierced through the fabric just distal to the slot 2733 from the outside and back, wrapping the third suture 2772c around the frame 2705. At FIG. 27D, two leaflets 2722a,b can be aligned, and leaflet protectors 2773 (e.g., made of a lubricious fabric, such as a polyester weave) can be placed along the outward-facing side of each arm 2795a,b of the leaflets 1022a,b. At FIG. 27E, the arms 2795a,b and leaflet protectors 2773a,b of the leaflets 1022a,b can remain flush. As shown in FIGS. 27G-I, the leaflet arms 2795a,b can be slid through the slot 2733. As shown in FIG. 27F, the arms 2795a,b can be positioned at approximately a 90 degree angle relative to the slot 2733. As shown at FIG. 27G, each arm 2795a,b can be slid through the slot 2733 until the beginning of the bump 2778 on the arm 2795a,b is flush with the inside of the slot 2733 (to do so, the inflow edges 2793 can be folded inward towards one another and the central axis. At FIG. 27H, the arms 2795a,b can be at approximately 90 degrees relative to the slot 2733 after being pulled therethrough. At FIG. 271, the two leaflets 2722a,b can be separated, and, at FIGS. 27J and 27K, the process can be repeated for each of the other slots and attachment points (e.g., two additional slots/leaflet attachment points). As shown at FIGS. 27L and 27M, the leaflet arms 2795a,b can be folded away from one another, and the leaflet protectors 2773a,b can be folded away from one another. As shown at FIG. 27N, the edges of each arm 2795a,b can be placed horizontal to the outflow plane and the side/vertical edges can be parallel with the strut members 2721. At FIG. 270, the plate 2727 can be placed onto the leaflet arms and aligned with the slot 2733. The vertical edges 2761 of the retaining plate 2727 can be aligned parallel with the vertical strut members 2721. The top 2762 of the retaining plate 2727 can be aligned with the outflow tips 2777 of the strut frame 2705. The center of the retaining plate 2727 can be aligned with the center of the slot 2733. At FIG. 27P, the first suture 2772a can be wound around the top set of indents 2773a,b in the plate 2727 and the third suture 2772c can be wound around the bottom set of indents 2773i,j. At FIG. 27Q, the second suture 2772b can be woven around the plate 2727 into the remaining indents 2773c-h in a crisscross pattern (dotted lines represent suture on the backside of the plate 2727). The process can be repeated at each of the commissure attachment points. The sutures can advantageously help prevent translation of the plate 2727 relative to the slot 2733 and frame 2705. Further, the plate 2727 and slot 2733 can advantageously securely attach the leaflets 2722 to the frame 2705 without damaging the frame 2705, leaflets 2722a,b, and/or skirt 2716.



FIGS. 33-34 show additional plate embodiments that are similar to plate 2727. Referring to FIG. 33A, the plate 3327 is similar to plate 2727 except that the indents 3373 are longer and have a different angle that the indents 2773 of plate 2727. Thus, the top sent of indents 3373a, b in the plate 3427 are at an angle of approximately 90 degrees relative to the longitudinal axis 3333 of the device. Indents 3373c,d are angled upwards at 30-60 degrees, such as approximately 45 degrees relative to the longitudinal axis 3333. Indents 3373e,f are angled downwards at 30-60 degrees, such as approximately 45 degrees, relative to the longitudinal axis 3333. Indents 3373g,h are angled upwards again at 30-60 degrees, such as approximately 45 degrees, relative to the longitudinal axis 3333, and intents 3373i are at an angle of approximately 90 degrees relative to the longitudinal axis 3333. Further, each of the intents 3373c-h extends 15-30%, such as 20-25% of the width of the plate 3327.


Referring to FIG. 34A, the plate 3427 is similar to plate 2727 except that the indents 3473 are all at an angle of substantially 90 degrees relative to the longitudinal axis 3433. Further, the inner edge of each of the indents 3473c-h has a substantially circular shape. The indents 3473c-h each extend approximately 10%-25%, such as 15%-20% of the width of the plate 3427.


In some embodiments, referring to FIG. 22, once the arms of the leaflets 2222 are attached to the strut frame 2205, the inflow edges can be sewn to the strut frame 2205. An exemplary sewing line 2525 (close to the rivets 2527 at the atrial end of the strut frame 2205) is shown in FIG. 22.


In some embodiments, a valve prosthesis as described herein can include a delivery system attachment mechanism. For example, as shown in FIGS. 2A-2B, the atrial tips 212 can each have a pin 215 extending therefrom (e.g., in the ventricular direction) around which tethers from a delivery system can be wound.


Another delivery system attachment mechanism is shown in FIGS. 29A-29E. The atrial tips 2912 each have a pin 2915 extending therefrom (e.g., in the ventricular direction). Each pin can be, for example, 0.030 inches long and approximately 0.012 inches thick. Further, as shown in FIG. 29E, the skirt 2916 can have slots 2985 therein that are aligned with the pins 2915. The slots 2985 can allow for the passage of the tethers therethrough (i.e., to provide access to the pins 2195).


An exemplary method of delivering a valve prosthesis 1700 (which can be any of the valves prostheses described herein) after attachment to the tethers of the delivery system is shown in FIGS. 17A-17J. At FIGS. 17A and 17B, the valve is packed inside of a sheath such that the tips of the ventricular anchor 1704 point towards the ventricular end (i.e., away from the central portion 1703) and the tips of the atrial anchor 1702 point towards the atrial end (i.e., away from the central portion 1703). The valve 1700 can be delivered, e.g., transseptally, to the native annulus in this packed positioned. At FIGS. 17C-E, the ventricular anchor 1704 is partially deployed, i.e., to allow the ventricular anchor 1704 to begin to flare outwards. In this embodiments, barbs on the device point radially outwards rather than towards the atrium during the initial deployment steps. At FIGS. 17F and G, the valve is pulled 1-3 cm towards the atrium to seat the ventricular anchor 1704 on the ventricular side of the annulus. At FIG. 17H, the ventricular anchor 1704 is fully deployed, allowing the barbs to extend into the tissue. At this point, the strut frame 1705 (holding leaflets) is also fully exposed. At FIG. 17I, the atrial anchor 1702 is partially released to allow the anchor 1702 to drop against the wall of the atrium. At FIG. 17J, the atrial anchor 1702 is fully released, and the valve 1700 is seated in place.


The valve prostheses described herein can advantageously pack to a very low packing length, such as less than 4 cm, less than 3.8 cm, less than 3.6 cm, less than 3.2 cm, or less than 3.0 cm for delivery with a 32 French catheter. This low axial packing length advantageously allows the prostheses to be delivered transseptally, e.g., be easily maneuvered around the bend through the septum.


Further, the cells and/or v-shaped patterns of the valve prostheses described herein can be specifically designed so as to ensure that the ventricular side doesn't flare out when delivered. For example, by making the atrial anchor flexible (e.g., with flexible members), the ventricular anchor is less likely to hook around when delivered. As another example, the radius of the valve (the anchor or the strut frame) can be tuned and/or the valve can be made more flexible in specific areas (of the anchor or the strut frame) so as to ensure that the valve is less prone to hooking/flaring out when delivered. That is, referring to FIGS. 13A and 13B, in one embodiment, a change in the radius of curvature in region 1401 will yield a change in the deployment angle ϕ of the ventricular anchor in region 1402. Decreasing the curvature in region 1401 will make the frame less prone to wrapping around the catheter tip when the ventricular anchor is exposed from the catheter. In another embodiment, by making region 1401 flexible, but leaving the remaining portions of the ventricular and atrial anchors relatively stiff, the deployment angle ϕ in region 1402 is less prone to wrapping around the catheter tip when the ventricular anchor is exposed from the catheter tip.


The valve prostheses described herein can advantageously avoid interference with blood flow through the valve. For example, the skirting and shape of the nitinol on the inflow (or atrial) portion of the valve can be contoured to provide smooth approach to the valve orifice. This helps decrease the risk of any turbulent flow or pockets of stagnant blood. As another example, the attachment point between the inner strut and the outer frame can be adjusted longitudinally to change the relative obstruction of the inner strut with blood flow and the ventricular sub-valvular apparatus. As yet another example, the skirting can be selectively applied to areas only in which there is a risk of blood escaping between the prosthesis and the anatomy. By allowing some cells to be open, particularly on the ventricular anchoring member, there is less impedance to flow.


Any of the valve features or structural details of any device embodiment described herein can be incorporated or combined with any of the other embodiments herein. For example, the central members described herein are not limited in use with the anchor assemblies and strut frames in the specific embodiment, but can be replaced with any of the features described in any other embodiment.


In use, when the devices described herein can be used as mitral valve replacements. In some embodiments, when the replacement heart valve has been delivered near the mitral valve, the ventricular anchor can be deployed first in a cardiac chamber, such as the ventricle, and retracted to a seated position against the valve orifice, such as the mitral valve orifice. Then the center portion and atrial anchor portion may be deployed in another cardiac chamber, such as the atrium, wherein the expansion and reconfiguration of the atrial anchor and the central portion sandwiches the valve orifice securely between the anchors that have been deployed on either side of the annulus. Other exemplary aspects of the methods of delivery described in U.S. Pat. No. 8,870,948, issued Oct. 28, 2014, in International Patent Application No. PCT/US2016/032546, filed May 13, 2016, titled “CARDIAC VALVE DELIVERY DEVICES AND SYSTEMS,” and in U.S. Provisional Patent Application Nos. 62/424,021 and 62/424,051, both filed Nov. 18, 2016 and titled “CARDIAC VALVE DELIVERY DEVICES AND SYSTEMS” all of which are incorporated by reference in their entireties.


When a feature or element is herein referred to as being “on” another feature or element, it can be directly on the other feature or element or intervening features and/or elements may also be present. In contrast, when a feature or element is referred to as being “directly on” another feature or element, there are no intervening features or elements present. It will also be understood that, when a feature or element is referred to as being “connected”, “attached” or “coupled” to another feature or element, it can be directly connected, attached or coupled to the other feature or element or intervening features or elements may be present. In contrast, when a feature or element is referred to as being “directly connected”, “directly attached” or “directly coupled” to another feature or element, there are no intervening features or elements present. Although described or shown with respect to one embodiment, the features and elements so described or shown can apply to other embodiments. It will also be appreciated by those of skill in the art that references to a structure or feature that is disposed “adjacent” another feature may have portions that overlap or underlie the adjacent feature.


Terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. For example, as used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, steps, operations, elements, components, and/or groups thereof. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items and may be abbreviated as “/”.


Spatially relative terms, such as “under”, “below”, “lower”, “over”, “upper” and the like, may be used herein for ease of description to describe one element or feature's relationship to another element(s) or feature(s) as illustrated in the figures. It will be understood that the spatially relative terms are intended to encompass different orientations of the device in use or operation in addition to the orientation depicted in the figures. For example, if a device in the figures is inverted, elements described as “under” or “beneath” other elements or features would then be oriented “over” the other elements or features. Thus, the exemplary term “under” can encompass both an orientation of over and under. The device may be otherwise oriented (rotated 90 degrees or at other orientations) and the spatially relative descriptors used herein interpreted accordingly. Similarly, the terms “upwardly”, “downwardly”, “vertical”, “horizontal” and the like are used herein for the purpose of explanation only unless specifically indicated otherwise.


Although the terms “first” and “second” may be used herein to describe various features/elements (including steps), these features/elements should not be limited by these terms, unless the context indicates otherwise. These terms may be used to distinguish one feature/element from another feature/element. Thus, a first feature/element discussed below could be termed a second feature/element, and similarly, a second feature/element discussed below could be termed a first feature/element without departing from the teachings of the present invention.


Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising” means various components can be co-jointly employed in the methods and articles (e.g., compositions and apparatuses including device and methods). For example, the term “comprising” will be understood to imply the inclusion of any stated elements or steps but not the exclusion of any other elements or steps.


As used herein in the specification and claims, including as used in the examples and unless otherwise expressly specified, all numbers may be read as if prefaced by the word “about” or “approximately,” even if the term does not expressly appear. The phrase “about” or “approximately” may be used when describing magnitude and/or position to indicate that the value and/or position described is within a reasonable expected range of values and/or positions. For example, a numeric value may have a value that is +/−0.1% of the stated value (or range of values), +/−1% of the stated value (or range of values), +/−2% of the stated value (or range of values), +/−5% of the stated value (or range of values), +/−10% of the stated value (or range of values), etc. Any numerical range recited herein is intended to include all sub-ranges subsumed therein.


Although various illustrative embodiments are described above, any of a number of changes may be made to various embodiments without departing from the scope of the invention as described by the claims. For example, the order in which various described method steps are performed may often be changed in alternative embodiments, and in other alternative embodiments one or more method steps may be skipped altogether. Optional features of various device and system embodiments may be included in some embodiments and not in others. Therefore, the foregoing description is provided primarily for exemplary purposes and should not be interpreted to limit the scope of the invention as it is set forth in the claims.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. As mentioned, other embodiments may be utilized and derived there from, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is, in fact, disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art upon reviewing the above description.

Claims
  • 1. A prosthetic mitral valve comprising: a valve support assembly configured to self-expand from a collapsed configuration to an expanded configuration and including an anchor assembly having a ventricular anchor, a central portion, and an atrial anchor, the anchor assembly including a plurality of diamond-shaped cells;a plurality of leaflets attached to the valve support assembly; anda plurality of retention hooks attached to the anchor assembly, when the valve support assembly is in the expanded configuration, each retention hook curving radially outwards and extending from an apex of a respective one of the plurality of diamond-shaped cells.
  • 2. The prosthetic mitral valve of claim 1, wherein the valve support assembly includes a strut frame positioned radially inward of the anchor assembly and attached to the anchor assembly.
  • 3. The prosthetic mitral valve of claim 2, wherein the plurality of leaflets are attached to the strut frame.
  • 4. The prosthetic mitral valve of claim 2, wherein the ventricular anchor is at a distal end of the valve support assembly and the atrial anchor is at a proximal end of the valve support assembly.
  • 5. The prosthetic mitral valve of claim 4, wherein the atrial anchor extends further proximally than does the strut frame.
  • 6. The prosthetic mitral valve of claim 1, wherein the atrial anchor flares radially outward in the expanded configuration.
  • 7. The prosthetic mitral valve of claim 1, wherein in the expanded configuration, a diameter of the atrial anchor is greater than a diameter of the central portion.
  • 8. The prosthetic mitral valve of claim 1, wherein at least some of the retention hooks point in the atrial direction.
  • 9. The prosthetic mitral valve of claim 1, wherein a thickness of each of the plurality of retention hooks is less than 1.6 mm.
  • 10. The prosthetic mitral valve of claim 1, wherein the plurality of retention hooks are integral with the valve support assembly.
  • 11. A prosthetic mitral valve comprising: a valve support assembly configured to self-expand from a collapsed configuration to an expanded configuration and including: an anchor assembly having a ventricular anchor, a central portion, and an atrial anchor, the anchor assembly including a plurality of cells;a strut frame positioned radially inward of the anchor assembly and attached to the anchor assembly;a plurality of leaflets attached to the strut frame; anda plurality of retention hooks attached to the anchor assembly, when the valve support assembly is in the expanded configuration, each retention hook curving radially outwards and extending from an apex of a respective one of the plurality of cells.
  • 12. The prosthetic mitral valve of claim 11, wherein the plurality of leaflets are attached to the strut frame.
  • 13. The prosthetic mitral valve of claim 12, wherein the ventricular anchor is at a distal end of the valve support assembly and the atrial anchor is at a proximal end of the valve support assembly.
  • 14. The prosthetic mitral valve of claim 13, wherein the atrial anchor extends further proximally than does the strut frame.
  • 15. The prosthetic mitral valve of claim 11, wherein the atrial anchor flares radially outward in the expanded configuration.
  • 16. The prosthetic mitral valve of claim 11, wherein in the expanded configuration, a diameter of the atrial anchor is greater than a diameter of the central portion.
  • 17. The prosthetic mitral valve of claim 11, wherein at least some of the retention hooks point in the atrial direction.
  • 18. The prosthetic mitral valve of claim 11, wherein a thickness of each of the plurality of retention hooks is less than 1.6 mm.
  • 19. The prosthetic mitral valve of claim 11, wherein the plurality of retention hooks are integral with the valve support assembly.
  • 20. The prosthetic mitral valve of claim 11, wherein each of the plurality of cells is diamond-shaped.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. application Ser. No. 16/012,666, filed Jun. 19, 2018, which is a continuation-in-part of International Patent Application No. PCT/US2018/014902, filed Jan. 23, 2018, titled “REPLACEMENT MITRAL VALVES”, which claims priority to U.S. Provisional Application No. 62/513,877, filed Jun. 1, 2017 and to U.S. Provisional Patent Application No. 62/449,498, filed Jan. 23, 2017, and titled “REPLACEMENT MITRAL VALVES,” the entireties of which are incorporated by reference herein. This application may also be related to International Patent Application No. PCT/US2016/032550, filed May 13, 2016, titled “REPLACEMENT MITRAL VALVES”, to U.S. patent application Ser. No. 14/170,388, filed Jan. 31, 2014, titled “SYSTEM AND METHOD FOR CARDIAC VALVE REPAIR AND REPLACEMENT,” now U.S. Pat. No. 8,870,948, and to U.S. patent application Ser. No. 14/677,320, filed Apr. 2, 2015, titled “REPLACEMENT CARDIAC VALVES AND METHODS OF USE AND MANUFACTURE,” the entireties of which are incorporated by reference herein.

US Referenced Citations (712)
Number Name Date Kind
3334629 Cohn Aug 1967 A
3409013 Berry Nov 1968 A
3540431 Mobin-Ubdin Nov 1970 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4233690 Akins Nov 1980 A
4291420 Reul Sep 1981 A
4326306 Poler Apr 1982 A
4423809 Mazzocco Jan 1984 A
4425908 Simon Jan 1984 A
4501030 Lane Feb 1985 A
4531943 Van Tassel et al. Jul 1985 A
4580568 Gianturco Apr 1986 A
4602911 Ahmadi et al. Jul 1986 A
4610688 Silvestrini et al. Sep 1986 A
4617932 Kornberg Oct 1986 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten Apr 1987 A
4662885 DiPisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4755181 Igoe Jul 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4834755 Silvestrini et al. May 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4927426 Dretler May 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5064435 Porter Nov 1991 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5209741 Spaeth May 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5350398 Pavcnik et al. Sep 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5405377 Cragg Apr 1995 A
5411552 Andersen et al. May 1995 A
5425762 Muller Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5476506 Lunn Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5507767 Maeda et al. Apr 1996 A
5534007 St. Germain et al. Jul 1996 A
5545133 Burns et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554183 Nazari Sep 1996 A
5554185 Block et al. Sep 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5645559 Hachtman et al. Jul 1997 A
5662671 Barbut et al. Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5693083 Baker et al. Dec 1997 A
5695498 Tower Dec 1997 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5725552 Kotula et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5769812 Stevens et al. Jun 1998 A
5807405 Vanney et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824064 Taheri Oct 1998 A
5843158 Lenker et al. Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5860966 Tower Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876448 Thompson et al. Mar 1999 A
5885228 Rosenman et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5907893 Ladno-Azizi et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5968070 Bley et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5984973 Girard et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6022370 Tower Feb 2000 A
6027525 Suh et al. Feb 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6093203 Uflacker Jul 2000 A
6113612 Swanson et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6142987 Tsugita Nov 2000 A
6162245 Jayaraman Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6174322 Schneidt Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6187016 Hedges et al. Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6206909 Hanada et al. Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6231544 Tsugita et al. May 2001 B1
6231551 Barbut May 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6277555 Duran et al. Aug 2001 B1
6309417 Spence et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352708 Duran et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379368 Corcoran et al. Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6411552 Chiba Jun 2002 B1
6416510 Altman et al. Jul 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440152 Gainor et al. Aug 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6540768 Diaz et al. Apr 2003 B1
6562058 Seguin et al. May 2003 B2
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6610077 Hancock et al. Aug 2003 B1
6616675 Evard et al. Sep 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6652571 White et al. Nov 2003 B1
6656206 Corcoran et al. Dec 2003 B2
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6712836 Berg et al. Mar 2004 B1
6712842 Gifford, III et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6714842 Ito Mar 2004 B1
6723122 Yang et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6752828 Thornton Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 St. Germain et al. Jul 2004 B2
6773454 Wholey et al. Aug 2004 B2
6776791 Stallings et al. Aug 2004 B1
6790218 Jayaraman Sep 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6849085 Marton Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911037 Gainor et al. Jun 2005 B2
6913614 Marino et al. Jul 2005 B2
6921397 Corcoran et al. Jul 2005 B2
6936058 Forde et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6945997 Kluynh et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6960220 Marino et al. Nov 2005 B2
6960224 Marino et al. Nov 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6984242 Campbell et al. Jan 2006 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7077861 Spence Jul 2006 B2
7087072 Marino et al. Aug 2006 B2
7115135 Corcoran et al. Oct 2006 B2
7122020 Mogul Oct 2006 B2
7144410 Marino et al. Dec 2006 B2
7166097 Barbut Jan 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7189258 Johnson et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7192435 Corcoran et al. Mar 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7235093 Gregorich Jun 2007 B2
7261732 Justino Aug 2007 B2
7320704 Lashinski et al. Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7374560 Ressemann et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7402171 Osborne et al. Jul 2008 B2
7413563 Corcoran et al. Aug 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7455689 Johnson Nov 2008 B2
7566336 Corcoran et al. Jul 2009 B2
7582104 Corcoran et al. Sep 2009 B2
7591848 Allen Sep 2009 B2
7625364 Corcoran et al. Dec 2009 B2
7632298 Hijikema et al. Dec 2009 B2
7658748 Marino et al. Feb 2010 B2
7691115 Corcoran et al. Apr 2010 B2
7712606 Salahieh et al. May 2010 B2
7722666 Lafontaine May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7749238 Corcoran et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7803184 McGuckin, Jr. et al. Sep 2010 B2
7803186 Li et al. Sep 2010 B1
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7896915 Guyenot et al. Mar 2011 B2
7905901 Corcoran et al. Mar 2011 B2
7927351 Corcoran et al. Apr 2011 B2
7972361 Corcoran et al. Jul 2011 B2
8043368 Crabtree Oct 2011 B2
8057540 Letac et al. Nov 2011 B2
8092520 Quadri Jan 2012 B2
8167935 McGuckin, Jr. et al. May 2012 B2
8236049 Rowe et al. Aug 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8366741 Chin et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8425593 Braido et al. Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8551132 Eskridge et al. Oct 2013 B2
8551161 Dolan Oct 2013 B2
8562672 Bonhoeffer et al. Oct 2013 B2
8568475 Nguyen et al. Oct 2013 B2
8579964 Lane et al. Nov 2013 B2
8579966 Seguin et al. Nov 2013 B2
8623074 Ryan Jan 2014 B2
8628566 Eberhardt et al. Jan 2014 B2
8673000 Tabor et al. Mar 2014 B2
8685080 White Apr 2014 B2
8721708 Seguin et al. May 2014 B2
8728155 Montorfano et al. May 2014 B2
8740962 Finch et al. Jun 2014 B2
8795356 Quadri et al. Aug 2014 B2
8801779 Seguin et al. Aug 2014 B2
8845722 Gabbay Sep 2014 B2
8852272 Gross et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8894702 Quadri et al. Nov 2014 B2
8911455 Quadri et al. Dec 2014 B2
8956404 Bortlein et al. Feb 2015 B2
8986375 Garde et al. Mar 2015 B2
8998976 Gregg et al. Apr 2015 B2
9011527 Li et al. Apr 2015 B2
9017399 Gross et al. Apr 2015 B2
9023074 Theobald et al. May 2015 B2
9023100 Quadri et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9060857 Nguyen et al. Jun 2015 B2
9101467 Eberhardt et al. Aug 2015 B2
9125740 Morriss et al. Sep 2015 B2
9132009 Hacohen et al. Sep 2015 B2
9155617 Carpentier et al. Oct 2015 B2
9168130 Straubinger et al. Oct 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9232994 Miller Jan 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9387071 Tuval et al. Jul 2016 B2
9393110 Levi et al. Jul 2016 B2
9393112 Tuval et al. Jul 2016 B2
9414852 Gifford, III et al. Aug 2016 B2
9414913 Beith et al. Aug 2016 B2
9421083 Eidenschink et al. Aug 2016 B2
9421098 Gifford, III et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9474605 Rowe et al. Oct 2016 B2
9474609 Haverkost et al. Oct 2016 B2
9480556 Revuelta et al. Nov 2016 B2
9480558 Destefano Nov 2016 B2
9480563 Li Nov 2016 B2
9486306 Tegels et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9498330 Solem Nov 2016 B2
9498332 Hacohen et al. Nov 2016 B2
9504564 Nguyen et al. Nov 2016 B2
9504568 Ryan et al. Nov 2016 B2
9510943 Mesana et al. Dec 2016 B2
9554899 Granada et al. Jan 2017 B2
9561100 Pintor et al. Feb 2017 B2
9561103 Granada et al. Feb 2017 B2
9579198 Deem et al. Feb 2017 B2
9655722 Morriss et al. May 2017 B2
9788941 Hacohen Oct 2017 B2
9867697 Alkhatib et al. Jan 2018 B2
9883941 Hastings et al. Feb 2018 B2
9949824 Bonhoeffer et al. Apr 2018 B2
10004601 Tuval et al. Jun 2018 B2
10070954 Braido et al. Sep 2018 B2
10143552 Wallace et al. Dec 2018 B2
10179042 Braido et al. Jan 2019 B2
10231827 Mulvihill Mar 2019 B2
10299921 Dale et al. May 2019 B2
10376361 Gross et al. Aug 2019 B2
10433953 Wallace et al. Oct 2019 B2
10449047 Hariton et al. Oct 2019 B2
10470881 Noe et al. Nov 2019 B2
20010007956 Letac et al. Jul 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020010489 Grayzel et al. Jan 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029981 Nigam Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020055769 Wang May 2002 A1
20020062135 Mazzocchi et al. May 2002 A1
20020082609 Green Jun 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020177766 Mogul Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20030023303 Palmaz et al. Jan 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030070944 Nigam Apr 2003 A1
20030074011 Gilboa et al. Apr 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149477 Gabbay Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030225421 Peavey et al. Dec 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20040034411 Quijano et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040060563 Rapacki et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040087982 Eskuri May 2004 A1
20040093016 Root et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040127849 Kantor Jul 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040143294 Corcoran et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040204755 Robin Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20050033402 Cully et al. Feb 2005 A1
20050038383 Kelley et al. Feb 2005 A1
20050070934 Tanaka et al. Mar 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050100580 Osborne et al. May 2005 A1
20050107822 WasDyke May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050209580 Freyman Sep 2005 A1
20050228472 Case et al. Oct 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060116717 Marino et al. Jun 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060190030 To et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060235510 Johnson et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265045 Shiu et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20070016286 Herrmann et al. Jan 2007 A1
20070055340 Pryor Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070100440 Figulla et al. May 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070255389 Oberti et al. Nov 2007 A1
20070265656 Amplatz et al. Nov 2007 A1
20070276324 Laduca et al. Nov 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080015619 Figulla et al. Jan 2008 A1
20080033543 Gurskis et al. Feb 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080140191 Mathis et al. Jun 2008 A1
20080167682 Corcoran et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234797 Styrc Sep 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090036768 Seehusen et al. Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090082803 Adams et al. Mar 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090182405 Arnault De La Menardiere et al. Jul 2009 A1
20090192585 Bloom et al. Jul 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090254165 Tabor et al. Oct 2009 A1
20090264759 Byrd Oct 2009 A1
20090287290 Macaulay et al. Nov 2009 A1
20090306768 Quadri Dec 2009 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100094314 Hernlund et al. Apr 2010 A1
20100114308 Maschke May 2010 A1
20100121434 Paul et al. May 2010 A1
20100161036 Pintor et al. Jun 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100219092 Salahieh et al. Sep 2010 A1
20100268204 Tieu et al. Oct 2010 A1
20100280495 Paul et al. Nov 2010 A1
20100284724 Cardia Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110022157 Essinger et al. Jan 2011 A1
20110034987 Kennedy Feb 2011 A1
20110166636 Rowe Jul 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110257723 McNamara Oct 2011 A1
20110264198 Murray, III et al. Oct 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110301702 Rust et al. Dec 2011 A1
20120016464 Seguin Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120059458 Buchbinder et al. Mar 2012 A1
20120078347 Braido et al. Mar 2012 A1
20120078360 Rafiee Mar 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120158129 Duffy et al. Jun 2012 A1
20120197283 Marchand et al. Aug 2012 A1
20120197391 Alkhatib et al. Aug 2012 A1
20130041447 Erb et al. Feb 2013 A1
20130041458 Lashinski et al. Feb 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130261737 Costello Oct 2013 A1
20130282110 Schweich, Jr. et al. Oct 2013 A1
20130282114 Schweich, Jr. et al. Oct 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130310923 Kheradvar et al. Nov 2013 A1
20130331931 Gregg et al. Dec 2013 A1
20140005771 Braido et al. Jan 2014 A1
20140005775 Alkhatib et al. Jan 2014 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140012368 Sugimoto et al. Jan 2014 A1
20140012374 Rankin Jan 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140052241 Harks et al. Feb 2014 A1
20140052244 Rolando et al. Feb 2014 A1
20140067048 Chau et al. Mar 2014 A1
20140081383 Eberhardt et al. Mar 2014 A1
20140107665 Shellenberger et al. Apr 2014 A1
20140128726 Quill et al. May 2014 A1
20140180391 Dagan et al. Jun 2014 A1
20140214157 Bortlein et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140236278 Argentine et al. Aug 2014 A1
20140243954 Shannon Aug 2014 A1
20140249622 Carmi et al. Sep 2014 A1
20140257476 Montorfano et al. Sep 2014 A1
20140277390 Ratz et al. Sep 2014 A1
20140277563 White Sep 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140330368 Gloss et al. Nov 2014 A1
20140330370 Matheny et al. Nov 2014 A1
20140371844 Dale et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150025623 Granada et al. Jan 2015 A1
20150039083 Rafiee Feb 2015 A1
20150045881 Lim Feb 2015 A1
20150066141 Braid et al. Mar 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150112430 Creaven et al. Apr 2015 A1
20150119637 Alvarez et al. Apr 2015 A1
20150135506 White May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150157457 Hacohen Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150223773 John et al. Aug 2015 A1
20150272737 Dale et al. Oct 2015 A1
20150302634 Florent et al. Oct 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351904 Cooper et al. Dec 2015 A1
20160038280 Morriss et al. Feb 2016 A1
20160089234 Gifford, III Mar 2016 A1
20160151153 Sandstrom et al. Jun 2016 A1
20160158000 Granada et al. Jun 2016 A1
20160158003 Wallace et al. Jun 2016 A1
20160166384 Olson et al. Jun 2016 A1
20160235529 Ma et al. Aug 2016 A1
20160278922 Braido et al. Sep 2016 A1
20160310267 Zeng et al. Oct 2016 A1
20160310269 Braido et al. Oct 2016 A1
20170035569 Deem et al. Feb 2017 A1
20170042675 Freudenthal Feb 2017 A1
20170049571 Gifford, III Feb 2017 A1
20170056169 Johnson et al. Mar 2017 A1
20170128203 Zhang et al. May 2017 A1
20170209261 Bortlein et al. Jul 2017 A1
20170209269 Conklin Jul 2017 A1
20170231762 Quadri et al. Aug 2017 A1
20170245991 Granada et al. Aug 2017 A1
20170325941 Wallace et al. Nov 2017 A1
20170325948 Wallace et al. Nov 2017 A1
20170354499 Granada et al. Dec 2017 A1
20180000580 Wallace et al. Jan 2018 A1
20180056043 von Oepen et al. Mar 2018 A1
20180092744 von Oepen et al. Apr 2018 A1
20180110622 Gregg et al. Apr 2018 A1
20180206983 Noe et al. Jul 2018 A1
20180206984 Noe et al. Jul 2018 A1
20180206985 Noe et al. Jul 2018 A1
20180206986 Noe et al. Jul 2018 A1
20180256327 Perszyk et al. Sep 2018 A1
20180296325 McLean Oct 2018 A1
20180296335 Miyashiro Oct 2018 A1
20180296339 McLean Oct 2018 A1
20180296341 Noe et al. Oct 2018 A1
20180333259 Dibie Nov 2018 A1
20200078167 Quijano et al. Mar 2020 A1
Foreign Referenced Citations (78)
Number Date Country
2018100602 Jun 2018 AU
2859666 Jun 2013 CA
1338951 Mar 2002 CN
0409929 Jan 1991 EP
0819013 Jan 1998 EP
0937439 Aug 1999 EP
1042045 Oct 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1059894 Dec 2000 EP
1078610 Feb 2001 EP
1229864 Aug 2002 EP
1340473 Sep 2003 EP
1356793 Oct 2003 EP
1430853 Jun 2004 EP
1469797 Nov 2005 EP
1600121 Nov 2005 EP
1616531 Jan 2006 EP
1819304 Aug 2007 EP
1849440 Oct 2007 EP
2654624 Oct 2013 EP
2124826 Jul 2014 EP
9504556 Feb 1995 WO
9529640 Nov 1995 WO
9614032 May 1996 WO
9624306 Aug 1996 WO
9836790 Aug 1998 WO
9857599 Dec 1998 WO
9944542 Sep 1999 WO
0009059 Feb 2000 WO
0044308 Aug 2000 WO
200044313 Aug 2000 WO
0067661 Nov 2000 WO
0105331 Jan 2001 WO
0135870 May 2001 WO
0164137 Sep 2001 WO
0236048 May 2002 WO
2002041789 May 2002 WO
02100297 Dec 2002 WO
2003003943 Jan 2003 WO
2003003949 Jan 2003 WO
03011195 Feb 2003 WO
03015851 Feb 2003 WO
2003030776 Apr 2003 WO
03094797 Nov 2003 WO
2004014256 Feb 2004 WO
2004019811 Mar 2004 WO
2004026117 Apr 2004 WO
2004041126 May 2004 WO
2004047681 Jun 2004 WO
2004066876 Aug 2004 WO
2004082536 Sep 2004 WO
2005037361 Apr 2005 WO
2005084595 Sep 2005 WO
2005087140 Sep 2005 WO
2009072122 Jun 2009 WO
2009108615 Sep 2009 WO
2009132187 Oct 2009 WO
2009137755 Nov 2009 WO
2010057262 May 2010 WO
2010141847 Dec 2010 WO
2011057087 May 2011 WO
2011081997 Jul 2011 WO
2012161786 Nov 2012 WO
2013158608 Oct 2013 WO
2013158613 Oct 2013 WO
2014121280 Aug 2014 WO
2014144247 Sep 2014 WO
2015127283 Aug 2015 WO
2016168609 Oct 2016 WO
2016183523 Nov 2016 WO
2016183526 Nov 2016 WO
2017035002 Mar 2017 WO
2017035434 Mar 2017 WO
2017122109 Jul 2017 WO
2017167759 Oct 2017 WO
2017218877 Dec 2017 WO
2019023385 Jan 2019 WO
Non-Patent Literature Citations (42)
Entry
Gregg et al.; U.S. Pat. Appl. No. 15/573,555 entitled “Cardiac valve delivery devices and systems,” filed Nov. 13, 2017.
Noe et al.; U.S. Pat. Appl. No. 16/012,666 entitled “Replacement mitral valves,” filed Jun. 19, 2018.
Noe et al.; U.S. Pat. Appl. No. 15/909,610 entitled “Replacement mitral valves,” filed Mar. 1, 2018.
Noe et al.; U.S. Pat. Appl. No. 15/909,881 entitled “Replacement mitral valves,” filed Mar. 1, 2018.
Noe et al.; U.S. Pat. Appl. No. 15/910,484 entitled “Replacement mitral valves,” filed Mar. 2, 2018.
Noe et al.; U.S. Pat. Appl. No. 15/908,701 entitled “Replacement mitral valves,” filed Feb. 28, 2018.
Wallace et al.; U.S. Appl. No. 15/669,788 entitled “Replacement cardiac valves and methods of use and manufacture,” filed Aug. 4, 2017.
Granada et al.; U.S. Appl. No. 15/688,701 entitled “System and method for cardiac valve repair and replacement,” filed Aug. 28, 2017.
Andersen et al.; Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs; Euro. Heart J.; 13(5): 704-708; May 1992.
Atwood et al.; Insertion of Heart Valves by Catheterization; Project Supervised by Prof. S. Muftu of Northeastern University, May 2002: pp. 36-40.
Bodnar et al. Replacement Cardiac Valves; (Chapter 13) Extinct cardiac valve prostheses. Pergamon Publishing Corporation. New York, Aug. 1991: pp. 307-322.
Boudjemline et al. Percutaneous implantation of a biological valve in the aorta to treat aortic valve insufficiency—a sheep study.f Med Sci. Monit; Apr. 2002; vol. 8, No. 4: BR113-116.
Boudjemline et al. “Percutaneous implantation of a valve in the descending aorta in lambs.” Euro. Heart J; Jul. 2002; 23: 1045-1049.
Boudjemline et al. “Percutaneous pulmonary valve replacement in a large right ventricular outflow tract: an experimental study.” Journal of the American College of Cardiology; Mar. 2004; vol. 43(6): 1082-1087.
Boudjemline et al. “Percutaneous valve insertion: A new approach?” J. of Thoracic and Cardio. Surg; Mar. 2003; 125(3): 741-743.
Boudjemline et al. “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation; Feb. 2002; 105: 775-778.
Cribier et al. “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coli. of Cardio; Feb. 2004; 43(4): 698-703.
Cribier et al. “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” Percutaneous Valve Technologies, Inc. 2002: 16 pages (year of pub. sufficiently earlier than effective US filedand any foreign priority date).
Cribier et al. “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” (slide presentation); TCT 2002 (conference); 16 pgs.; Washington D.C.; Sep. 24-28, 2002.
Ferrari et al. “Percutaneous transvascular aortic valve replacement with self expanding stent-valve device.” Poster from the presentation given at SMIT 2000, 12th International Conference. 1 pg. Sep. 5, 2000.
Granada et al.; U.S. Appl. No. 16/224,221 entitled “System and method for cardiac valve repair and replacement,” filed Dec. 18, 2018.
Hijazi “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardia; Mar. 2004; 43(6): 1088-1089.
Huber et al. “Do valved stents compromise coronary flow?” European Journal of Cardio-thoracic Surgery; May 2004; vol. 25: 754-759.
Knudsen et al. “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs; May 1993; 16(5): 253-262.
Kort et al. “Minimally invasive aortic valve replacement: Echocardiographic and clinical results.” Am. Heart J; Sep. 2001; 142(3): 476-481.
Love et al. The Autogenous Tissue Heart Valve: Current Stat. Journal of Cardiac Surgery; Dec. 1991; 6(4): 499-507.
Lutter et al. “Percutaneous aortic valve replacement: An experimental study. I. Studies on implantation.” J. of Thoracic and Cardio. Surg; Apr. 2002; 123(4 ): 768-776.
Moulopoulos et al. “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg; May 1971; 11(5): 423-430.
Paniagua et al. “Percutaneous heart valve in the chronic in vitro testing model.” Circulation; Sep. 2002; 106: e51-e52.
Paniagua et al. Heart Watch (2004). Texas Heart Institute. Spring (Mar.) 2004 Edition: 8 pages.
Pavcnik et al. “Percutaneous bioprosthetic veno valve: A long-term study in sheep.” J. of Vascular Surg; Mar. 2002; 35(3): 598-603.
Phillips et al. “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg; Feb. 1976; 21 (2): 134-136.
Sochman et al. “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Lntervent. Radiol; Sep.-Oct. 2000; 23: 384-388.
Solvay; Novel revivent(tm) Myocardial anchoring system from bioVentrix uses solvay's zeniva® PEEK in tether component; 3 pages retrieved from the internet (http://www.solvay.com/en/media/press_release/20131205-novel-revivent-myocardial-anchoring-system-bioventrix-uses-zenivapeek.html); (Press Release); on Aug. 10, 2017.
Stuart, M. “In Heart Valves, a Brave, New Non-Surgical World.” Start-Up; Feb. 2004: 9-17.
Vahanian et al. “Percutaneous Approaches to Valvular Disease.” Circulation; Apr. 2004; 109:1572-1579.
Van Herwerden et al., “Percutaneous valve implantation: back to the future?” Euro. Heart J; Sep. 2002; 23(18): 1415-1416.
Zhou et al. “Self-expandable valved stent of large size: off-bypass implantation in pulmonary position.” Eur. J. Cardiothorac; Aug. 2003; 24: 212-216.
Wallace et al., U.S. Appl. No. 16/310,499 entitled “Cardiac valve delivery devices and systems,” filed Dec. 17, 2018.
Australian Notice of Acceptance for Application No. AU 2018203053 dated Feb. 13, 2020, 3 pages.
Australian Examination Report for Application No. 2016262564 dated Feb. 19, 2020, 5 pages.
International Search Report including the Written Opinion from Application No. PCT/US2019/037729 dated Aug. 21, 2019, pp. 1-11.
Related Publications (1)
Number Date Country
20190328525 A1 Oct 2019 US
Provisional Applications (2)
Number Date Country
62513877 Jun 2017 US
62449498 Jan 2017 US
Continuations (1)
Number Date Country
Parent 16012666 Jun 2018 US
Child 16506166 US
Continuation in Parts (1)
Number Date Country
Parent PCT/US2018/014902 Jan 2018 US
Child 16012666 US